{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T19:24:43Z","timestamp":1793388283686,"version":"4.5.0"},"reference-count":652,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2015,4,7]],"date-time":"2015-04-07T00:00:00Z","timestamp":1428364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Spanish Government","award":["SAF-2013-45232R"],"award-info":[{"award-number":["SAF-2013-45232R"]}]},{"DOI":"10.13039\/100016077","name":"EU","doi-asserted-by":"publisher","award":["ICRES-261202"],"award-info":[{"award-number":["ICRES-261202"]}],"id":[{"id":"10.13039\/100016077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill &amp; Melinda Gates Foundation","doi-asserted-by":"publisher","award":["CAVD-PTVDC"],"award-info":[{"award-number":["CAVD-PTVDC"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>After Edward Jenner established human vaccination over 200 years ago, attenuated poxviruses became key players to contain the deadliest virus of its own family: Variola virus (VARV), the causative agent of smallpox. Cowpox virus (CPXV) and horsepox virus (HSPV) were extensively used to this end, passaged in cattle and humans until the appearance of vaccinia virus (VACV), which was used in the final campaigns aimed to eradicate the disease, an endeavor that was accomplished by the World Health Organization (WHO) in 1980. Ever since, naturally evolved strains used for vaccination were introduced into research laboratories where VACV and other poxviruses with improved safety profiles were generated. Recombinant DNA technology along with the DNA genome features of this virus family allowed the generation of vaccines against heterologous diseases, and the specific insertion and deletion of poxvirus genes generated an even broader spectrum of modified viruses with new properties that increase their immunogenicity and safety profile as vaccine vectors. In this review, we highlight the evolution of poxvirus vaccines, from first generation to the current status, pointing out how different vaccines have emerged and approaches that are being followed up in the development of more rational vaccines against a wide range of diseases.<\/jats:p>","DOI":"10.3390\/v7041726","type":"journal-article","created":{"date-parts":[[2015,4,8]],"date-time":"2015-04-08T03:01:07Z","timestamp":1428462067000},"page":"1726-1803","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":192,"title":["The Evolution of Poxvirus Vaccines"],"prefix":"10.3390","volume":"7","author":[{"given":"Lucas","family":"S\u00e1nchez-Sampedro","sequence":"first","affiliation":[{"name":"Department of Molecular and Cellular Biology, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Madrid-28049, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Perdiguero","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Madrid-28049, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Mej\u00edas-P\u00e9rez","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Madrid-28049, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Garc\u00eda-Arriaza","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Madrid-28049, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Di Pilato","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Madrid-28049, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Esteban","sequence":"additional","affiliation":[{"name":"Department of Molecular and Cellular Biology, Centro Nacional de Biotecnolog\u00eda, Consejo Superior de Investigaciones Cient\u00edficas (CSIC), Madrid-28049, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2015,4,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Hopkins, D.R. (2002). The Greatest Killer: Smallpox in History, with a New Introduction, University of Chicago Press.","DOI":"10.7208\/chicago\/9780226189529.001.0001"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jaci.2006.09.037","article-title":"Smallpox vaccines: Past, present, and future","volume":"118","author":"Parrino","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_3","first-page":"45","article-title":"The links between the medical school of Padua and the Hellenic medical world","volume":"4","author":"Marketos","year":"1992","journal-title":"Med. Secoli."},{"key":"ref_4","first-page":"21","article-title":"Edward Jenner and the history of smallpox and vaccination","volume":"18","author":"Riedel","year":"2005","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/vr.f5587","article-title":"Has horsepox become extinct?","volume":"173","author":"Esparza","year":"2013","journal-title":"Vet. Rec."},{"key":"ref_6","first-page":"84","article-title":"On the vaccination before and after Jenner","volume":"63","year":"2011","journal-title":"Rev. Invest. Clin."},{"key":"ref_7","first-page":"562","article-title":"The royal philanthropic expedition of the vaccine (Xavier de Balmis\/Josep Salvany). 1803\u20131806","volume":"26","author":"Botet","year":"2009","journal-title":"Rev. Chil. Infectol."},{"key":"ref_8","unstructured":"Arita, I., Jezek, Z., and Ladnyi, I.D. (1988). Smallpox and Its Erradication, World Health Organization."},{"key":"ref_9","unstructured":"W.H.O. (1979\u20131980). The Global Eradication of Smallpox. Final Report of the Global Commision for the Certification of Smallpox Eradication, World Health Organization."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/0042-6822(60)90200-2","article-title":"Genetic studies with mammalian poxviruses. IV. Hybridization between several different poxviruses","volume":"12","author":"Woodroofe","year":"1960","journal-title":"Virology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1073\/pnas.79.5.1593","article-title":"Molecular genetics of vaccinia virus: Demonstration of marker rescue","volume":"79","author":"Nakano","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1073\/pnas.79.4.1210","article-title":"Mapping of the vaccinia virus thymidine kinase gene by marker rescue and by cell-free translation of selected mRNA","volume":"79","author":"Weir","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1073\/pnas.79.16.4927","article-title":"Construction of poxviruses as cloning vectors: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus","volume":"79","author":"Panicali","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.79.23.7415","article-title":"Vaccinia virus: A selectable eukaryotic cloning and expression vector","volume":"79","author":"Mackett","year":"1982","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/302490a0","article-title":"Infectious vaccinia virus recombinants that express hepatitis B virus surface antigen","volume":"302","author":"Smith","year":"1983","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"7155","DOI":"10.1073\/pnas.80.23.7155","article-title":"Construction and characterization of an infectious vaccinia virus recombinant that expresses the influenza hemagglutinin gene and induces resistance to influenza virus infection in hamsters","volume":"80","author":"Smith","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1073\/pnas.80.17.5364","article-title":"Construction of live vaccines by using genetically engineered poxviruses: Biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin","volume":"80","author":"Panicali","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0264-410X(84)90086-0","article-title":"Genetically engineered poxviruses: A novel approach to the construction of live vaccines","volume":"2","author":"Paoletti","year":"1984","journal-title":"Vaccine"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0042-6822(88)90692-7","article-title":"Successful oral rabies vaccination of raccoons with raccoon poxvirus recombinants expressing rabies virus glycoprotein","volume":"165","author":"Esposito","year":"1988","journal-title":"Virology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1016\/j.vaccine.2013.03.042","article-title":"Reflections on the early development of poxvirus vectors","volume":"31","author":"Moss","year":"2013","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0042-6822(90)90294-2","article-title":"The complete DNA sequence of vaccinia virus","volume":"179","author":"Goebel","year":"1990","journal-title":"Virology"},{"key":"ref_22","unstructured":"Jenner, E. (1909\u20131914). The Three Original Publications On Vaccination Against Smallpox, P.F. Collier & Son. Part 4 of 8."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1136\/bmj.1.6073.1379","article-title":"Is cowpox misnamed? A review of 10 human cases","volume":"1","author":"Baxby","year":"1977","journal-title":"Br. Med. J."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/BF01246382","article-title":"Experimental studies on transformation of the variola virus into the vaccinia virus","volume":"12","author":"Herrlich","year":"1963","journal-title":"Arch. Gesamte Virusforsch."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/path.1700910220","article-title":"Adaptation of variola virus to growth in the rabbit","volume":"91","author":"Dumbell","year":"1966","journal-title":"J. Pathol. Bacteriol."},{"key":"ref_26","unstructured":"Mudd, S. (1970). Infectious Agents and Host Reactions, WB Saunders Co."},{"key":"ref_27","unstructured":"Dekking, F. (1964). Cowpox and Vaccinia, Elsevier."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Qin, L., Favis, N., Famulski, J., and Evans, D.H. (2014). The evolution and evolutionary relationships between extant vaccinia virus strains. J. Virol.","DOI":"10.1128\/JVI.02797-14"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"13049","DOI":"10.1128\/JVI.05779-11","article-title":"Genomic analysis of the vaccinia virus strain variants found in Dryvax vaccine","volume":"85","author":"Qin","year":"2011","journal-title":"J. Virol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1128\/JVI.79.18.11873-11891.2005","article-title":"An attenuated LC16m8 smallpox vaccine: Analysis of full-genome sequence and induction of immune protection","volume":"79","author":"Morikawa","year":"2005","journal-title":"J. Virol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.1016\/j.vaccine.2007.10.040","article-title":"Genomic differences of Vaccinia virus clones from Dryvax smallpox vaccine: The Dryvax-like ACAM2000 and the mouse neurovirulent Clone-3","volume":"25","author":"Osborne","year":"2007","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1099\/vir.0.82708-0","article-title":"Genomic sequence of a clonal isolate of the vaccinia virus Lister strain employed for smallpox vaccination in France and its comparison to other orthopoxviruses","volume":"88","author":"Garcel","year":"2007","journal-title":"J. Gen. Virol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e23086","DOI":"10.1371\/journal.pone.0023086","article-title":"Chasing Jenner\u2019s vaccine: Revisiting cowpox virus classification","volume":"6","author":"Carroll","year":"2011","journal-title":"PLOS ONE"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.3390\/v2091933","article-title":"Orthopoxvirus genome evolution: The role of gene loss","volume":"2","author":"Hendrickson","year":"2010","journal-title":"Viruses"},{"key":"ref_35","unstructured":"Creighton, C. (1889). Jenner and Vaccination, a Strange Chapter of Medical History, Swan sonnenschein & CO."},{"key":"ref_36","unstructured":"Drewitt, F.D. (1933). The Life of Edward Jenner, Cambridge University Press."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.06.006","article-title":"Vaccinia virus vaccines: Past, present and future","volume":"84","author":"Jacobs","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"9244","DOI":"10.1128\/JVI.00945-06","article-title":"Genome of horsepox virus","volume":"80","author":"Tulman","year":"2006","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1751-0813.1989.tb09788.x","article-title":"Experimental vaccinia virus infection of horses","volume":"66","author":"Studdert","year":"1989","journal-title":"Aust. Vet. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1542\/peds.42.6.980","article-title":"Smallpox vaccination of eczema patients with a strain of attenuated live vaccinia (CVI-78)","volume":"42","author":"Kempe","year":"1968","journal-title":"Pediatrics"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1203\/00006450-197508000-00003","article-title":"Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. II. Clinical and serologic observations of response to revaccination with calf lymph vaccine","volume":"9","author":"Speers","year":"1975","journal-title":"Pediatr. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1203\/00006450-197508000-00002","article-title":"Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. I. Clinical and serologic response to primary vaccination","volume":"9","author":"Wesley","year":"1975","journal-title":"Pediatr. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1084\/jem.74.3.263","article-title":"Further Studies of the Infectious Unit of Vaccinia","volume":"74","author":"Parker","year":"1941","journal-title":"J. Exp. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1001\/jama.292.10.1205","article-title":"Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine: A randomized controlled trial","volume":"292","author":"Talbot","year":"2004","journal-title":"JAMA"},{"key":"ref_45","unstructured":"Available online:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003900.pdf."},{"key":"ref_46","first-page":"37","article-title":"Comparative study of the smallpox vaccines from B-51, EM-63 and L-IVP in a controlled epidemiological experiment. II. The characteristiics of the immunogenicity of the smallpox vaccines","volume":"9","author":"Khliabich","year":"1978","journal-title":"Zh Mikrobiol. Epidemiol. Immunobiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1086\/432765","article-title":"Clinical responses to smallpox vaccine in vaccinia-naive and previously vaccinated populations: Undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized, prospective trial","volume":"192","author":"Kim","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.virol.2013.03.025","article-title":"Genomic analysis of vaccinia virus strain TianTan provides new insights into the evolution and evolutionary relationships between Orthopoxviruses","volume":"442","author":"Qin","year":"2013","journal-title":"Virology"},{"key":"ref_49","unstructured":"Alan, D.T., and Barret, L.R.S. (2009). Vaccines for Biodefense and Emerging and Neglected Diseases, Academic Press\/Elsevier."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF01319903","article-title":"Poxvirus hosts and reservoirs. Brief review","volume":"55","author":"Baxby","year":"1977","journal-title":"Arch. Virol."},{"key":"ref_51","first-page":"279","article-title":"Large-scale use of freeze-dried smallpox vaccine prepared in primary cultures of rabbit kidney cells","volume":"54","author":"Hekker","year":"1976","journal-title":"Bull. World Health Organ."},{"key":"ref_52","unstructured":"Meyer, H. (2013). Summary Report on Firs, Second and Third Generation Smallpox Vaccines, World Health Organization."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/milmed\/165.4.287","article-title":"Adverse reactions to smallpox vaccine: The Israel Defense Force experience, 1991 to 1996. A comparison with previous surveys","volume":"165","author":"Haim","year":"2000","journal-title":"Mil. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1086\/423851","article-title":"Clinical and immune responses after revaccination of israeli adults with the Lister strain of vaccinia virus","volume":"190","author":"Orr","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"8290","DOI":"10.1016\/j.vaccine.2007.09.050","article-title":"Safety, immunogenicity and protective efficacy in mice of a new cell-cultured Lister smallpox vaccine candidate","volume":"25","author":"Drillien","year":"2007","journal-title":"Vaccine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"7845","DOI":"10.1128\/JVI.79.12.7845-7851.2005","article-title":"Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus","volume":"79","author":"Stittelaar","year":"2005","journal-title":"J. Virol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/j.vaccine.2006.09.046","article-title":"An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies","volume":"25","author":"Wiser","year":"2007","journal-title":"Vaccine"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0140-6736(05)70234-8","article-title":"Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: A blind, single-centre, randomised controlled trial","volume":"365","author":"Greenberg","year":"2005","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1038\/nm916","article-title":"Clonal vaccinia virus grown in cell culture as a new smallpox vaccine","volume":"9","author":"Weltzin","year":"2003","journal-title":"Nat. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ijid.2004.09.002","article-title":"ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)\u2014A second-generation smallpox vaccine for biological defense","volume":"8","author":"Monath","year":"2004","journal-title":"Int. J. Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.1016\/j.vaccine.2010.06.063","article-title":"A randomized, double-blind, controlled clinical trial to evaluate the efficacy and safety of CJ-50300, a newly developed cell culture-derived smallpox vaccine, in healthy volunteers","volume":"28","author":"Jang","year":"2010","journal-title":"Vaccine"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1001\/jama.289.24.3278","article-title":"US military smallpox vaccination program experience","volume":"289","author":"Grabenstein","year":"2003","journal-title":"JAMA"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1186\/1743-422X-3-88","article-title":"Genomic sequence and analysis of a vaccinia virus isolate from a patient with a smallpox vaccine-related complication","volume":"3","author":"Li","year":"2006","journal-title":"Virol. J."},{"key":"ref_64","first-page":"175","article-title":"Analysis of antibody formation to the vaccinia virus in human subjects and rabbits in response to the administration of a recombinant vaccinia-hepatitis B vaccine","volume":"33","author":"Cheliapov","year":"1988","journal-title":"Vopr. Virusol."},{"key":"ref_65","first-page":"132","article-title":"Verification of the safety, inoculability, reactogenicity and antigenic properties of a live recombinant smallpox-hepatitis B vaccine in an experiment in volunteers","volume":"35","author":"Chernos","year":"1990","journal-title":"Vopr. Virusol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1016\/j.vaccine.2011.04.093","article-title":"Vaccinia virus as a vaccine delivery system for marsupial wildlife","volume":"29","author":"Cross","year":"2011","journal-title":"Vaccine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(87)90767-7","article-title":"Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever","volume":"2","author":"Clegg","year":"1987","journal-title":"Lancet"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.4049\/jimmunol.0803467","article-title":"Vaccinia virus-based multivalent H5N1 avian influenza vaccines adjuvanted with IL-15 confer sterile cross-clade protection in mice","volume":"182","author":"Poon","year":"2009","journal-title":"J. Immunol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1073\/pnas.1403684111","article-title":"IL-15 adjuvanted multivalent vaccinia-based universal influenza vaccine requires CD4+ T cells for heterosubtypic protection","volume":"111","author":"Valkenburg","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/0264-410X(96)00008-4","article-title":"Influence of the parental virus strain on the virulence and immunogenicity of recombinant vaccinia viruses expressing HBV preS2-S protein or VZV glycoprotein I","volume":"14","author":"Kutinova","year":"1996","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1073\/pnas.88.18.8011","article-title":"A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions","volume":"88","author":"Giavedoni","year":"1991","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0168-1702(88)90033-0","article-title":"Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection","volume":"9","author":"Auperin","year":"1988","journal-title":"Virus Res."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"18091","DOI":"10.1073\/pnas.1013083107","article-title":"Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities","volume":"107","author":"Merkel","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7194","DOI":"10.1073\/pnas.81.22.7194","article-title":"Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene","volume":"81","author":"Wiktor","year":"1984","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S0950268800052535","article-title":"The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur","volume":"116","author":"Pastoret","year":"1996","journal-title":"Epidemiol. Infect."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/0264-410X(91)90187-B","article-title":"High expression of human cytomegalovirus (HCMV)-gB protein in cells infected with a vaccinia-gB recombinant: The importance of the gB protein in HCMV immunity","volume":"9","author":"Gonczol","year":"1991","journal-title":"Vaccine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/0264-410X(95)00232-P","article-title":"Protection of rabbits against rabbit viral haemorrhagic disease with a vaccinia-RHDV recombinant virus","volume":"14","author":"Bertagnoli","year":"1996","journal-title":"Vaccine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1099\/0022-1317-73-2-359","article-title":"Construction of vaccinia virus recombinants expressing several measles virus proteins and analysis of their efficacy in vaccination of mice","volume":"73","author":"Wild","year":"1992","journal-title":"J. Gen. Virol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1128\/jvi.63.10.4189-4198.1989","article-title":"Expression in recombinant vaccinia virus of the equine herpesvirus 1 gene encoding glycoprotein gp13 and protection of immunized animals","volume":"63","author":"Guo","year":"1989","journal-title":"J. Virol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/ije\/23.1.169","article-title":"Antibodies to the 4-m repeat of the ring-infected erythrocyte surface antigen (Pf155\/RESA) protect against Plasmodium falciparum malaria","volume":"23","author":"Astagneau","year":"1994","journal-title":"Int. J. Epidemiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1128\/iai.62.8.3270-3275.1994","article-title":"Immunogenicity of the Plasmodium falciparum glutamate-rich protein expressed by vaccinia virus","volume":"62","author":"Theisen","year":"1994","journal-title":"Infect. Immun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"e34445","DOI":"10.1371\/journal.pone.0034445","article-title":"Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium","volume":"7","author":"Rodriguez","year":"2012","journal-title":"PLOS ONE"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e25938","DOI":"10.1371\/journal.pone.0025938","article-title":"A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus","volume":"6","author":"Goodman","year":"2011","journal-title":"PLOS ONE"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S0264-410X(01)00389-9","article-title":"Enhanced CD8+ T cell immune response against a V3 loop multi-epitope polypeptide (TAB13) of HIV-1 Env after priming with purified fusion protein and booster with modified vaccinia virus Ankara (MVA-TAB) recombinant: A comparison of humoral and cellular immune responses with the vaccinia virus Western Reserve (WR) vector","volume":"20","author":"Gomez","year":"2001","journal-title":"Vaccine"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7048","DOI":"10.1128\/JVI.77.12.7048-7057.2003","article-title":"Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes","volume":"77","author":"Gherardi","year":"2003","journal-title":"J. Virol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.virusres.2004.04.008","article-title":"Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime\/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma","volume":"105","author":"Gomez","year":"2004","journal-title":"Virus Res."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5286","DOI":"10.1128\/IAI.73.8.5286-5289.2005","article-title":"Heterologous prime-boost vaccination with the LACK antigen protects against murine visceral leishmaniasis","volume":"73","author":"Dondji","year":"2005","journal-title":"Infect. Immun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.vaccine.2007.11.021","article-title":"Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response","volume":"26","author":"Ramos","year":"2008","journal-title":"Vaccine"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0165-2478(93)90099-N","article-title":"Immunogenicity of recombinant vaccinia viruses expressing hepatitis B virus surface antigen in mice","volume":"36","author":"Grigorieva","year":"1993","journal-title":"Immunol. Lett."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1128\/iai.59.6.1961-1965.1991","article-title":"Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals","volume":"59","author":"Welkos","year":"1991","journal-title":"Infect. Immun."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/jvi.64.6.2788-2795.1990","article-title":"Induction of protective immunity in animals vaccinated with recombinant vaccinia viruses that express PreM and E glycoproteins of Japanese encephalitis virus","volume":"64","author":"Yasuda","year":"1990","journal-title":"J. Virol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0042-6822(89)90346-2","article-title":"Immunization with a vaccinia recombinant expressing the F protein protects rabbits from challenge with a lethal dose of rinderpest virus","volume":"170","author":"Barrett","year":"1989","journal-title":"Virology"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/BF01319233","article-title":"Immunological and virological characterization of improved construction of recombinant vaccinia virus expressing rinderpest virus hemagglutinin","volume":"116","author":"Asano","year":"1991","journal-title":"Arch. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1006\/viro.2000.0564","article-title":"Evaluation of recombinant vaccinia virus\u2014Measles vaccines in infant rhesus macaques with preexisting measles antibody","volume":"276","author":"Zhu","year":"2000","journal-title":"Virology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1128\/CDLI.7.1.114-118.2000","article-title":"Characterization of specific immune responses of mice inoculated with recombinant vaccinia virus expressing an 18-kilodalton outer membrane protein of Brucella abortus","volume":"7","author":"Vemulapalli","year":"2000","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/0264-410X(88)90104-1","article-title":"Evaluation in non-human primates of the safety, immunogenicity and efficacy of recombinant vaccinia viruses expressing the F or G glycoprotein of respiratory syncytial virus","volume":"6","author":"Olmsted","year":"1988","journal-title":"Vaccine"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/978-1-4684-5823-7_30","article-title":"Immunogenicity of recombinant feline infectious peritonitis virus spike protein in mice and kittens","volume":"276","author":"Vennema","year":"1990","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"225","DOI":"10.7589\/0090-3558-36.2.225","article-title":"Characterization of poxviruses from forest birds in Hawaii","volume":"36","author":"Tripathy","year":"2000","journal-title":"J. Wildl. Dis."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/03079459994434","article-title":"Avian host spectrum of avipoxviruses","volume":"28","author":"Bolte","year":"1999","journal-title":"Avian Pathol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1128\/JVI.74.8.3815-3831.2000","article-title":"The genome of fowlpox virus","volume":"74","author":"Afonso","year":"2000","journal-title":"J. Virol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1128\/JVI.78.1.353-366.2004","article-title":"The genome of canarypox virus","volume":"78","author":"Tulman","year":"2004","journal-title":"J. Virol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2460\/ajvr.1985.46.02.529","article-title":"Morphogenesis of canary poxvirus and its entrance into inclusion bodies","volume":"46","author":"Sadasiv","year":"1985","journal-title":"Am. J. Vet. Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/0264-410X(88)90091-6","article-title":"Fowlpox virus as a vector in non-avian species","volume":"6","author":"Taylor","year":"1988","journal-title":"Vaccine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.virusres.2004.10.009","article-title":"Avipoxvirus multiplication in a mammalian cell line","volume":"109","author":"Weli","year":"2005","journal-title":"Virus Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1006\/viro.1993.1608","article-title":"Fowlpox virus host range restriction: Gene expression, DNA replication, and morphogenesis in nonpermissive mammalian cells","volume":"197","author":"Somogyi","year":"1993","journal-title":"Virology"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.antiviral.2010.07.005","article-title":"Canarypox and fowlpox viruses as recombinant vaccine vectors: A biological and immunological comparison","volume":"88","author":"Zanotto","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/0264-410X(92)90411-C","article-title":"Potential use of non-replicating vectors as recombinant vaccines","volume":"10","author":"Baxby","year":"1992","journal-title":"Vaccine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/14760584.4.1.63","article-title":"Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry","volume":"4","author":"Skinner","year":"2005","journal-title":"Expert Rev. Vaccines"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"S75","DOI":"10.1586\/14760584.3.4.S75","article-title":"Poxvirus-based vaccine candidates for HIV: Two decades of experience with special emphasis on canarypox vectors","volume":"3","author":"Franchini","year":"2004","journal-title":"Expert Rev. Vaccines"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/0264-410X(88)90100-4","article-title":"Recombinant fowlpox virus inducing protective immunity in non-avian species","volume":"6","author":"Taylor","year":"1988","journal-title":"Vaccine"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1186\/1743-422X-8-49","article-title":"Avipoxviruses: Infection biology and their use as vaccine vectors","volume":"8","author":"Weli","year":"2011","journal-title":"Virol. J."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/0264-410X(94)90181-3","article-title":"Humoral and cell-mediated immunity in rabbits immunized with live non-replicating avipox recombinants expressing the HIV-1SF2 env gene","volume":"12","author":"Radaelli","year":"1994","journal-title":"Vaccine"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.vaccine.2005.09.044","article-title":"Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials","volume":"24","author":"Coupar","year":"2006","journal-title":"Vaccine"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"13819","DOI":"10.1128\/JVI.78.24.13819-13828.2004","article-title":"Efficacy of DNA and fowlpox virus priming\/boosting vaccines for simian\/human immunodeficiency virus","volume":"78","author":"Dale","year":"2004","journal-title":"J. Virol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1034\/j.1600-0684.2000.290317.x","article-title":"Induction of HIV-1-specific T-helper responses and type 1 cytokine secretion following therapeutic vaccination of macaques with a recombinant fowlpoxvirus co-expressing interferon-gamma","volume":"29","author":"Dale","year":"2000","journal-title":"J. Med. Primatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1016\/S0264-410X(99)00559-9","article-title":"A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques","volume":"18","author":"Kent","year":"2000","journal-title":"Vaccine"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1574-695X.2003.tb00649.x","article-title":"Evaluation in rabbits of different anti-SHIV vaccine strategies based on DNA\/fowlpox priming and virus-like particle boosting","volume":"35","author":"Zanotto","year":"2003","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.vaccine.2003.08.028","article-title":"Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques","volume":"22","author":"Nacsa","year":"2004","journal-title":"Vaccine"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1042\/BA20040065","article-title":"A vaccination strategy consisting of Semliki-Forest-virus (SFV) DNA prime and fowlpox-virus boost significantly protects mice from a recombinant (HIV-1) vaccinia-virus infection","volume":"41","year":"2005","journal-title":"Biotechnol. Appl. Biochem."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e958404","DOI":"10.1155\/2012\/958404","article-title":"Protection against SHIV-KB9 infection by combining rDNA and rFPV vaccines based on HIV multiepitope and p24 protein in Chinese rhesus macaques","volume":"2012","author":"Li","year":"2012","journal-title":"Clin. Dev. Immunol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jviromet.2005.06.009","article-title":"Construction and characterization of recombinant fowlpox virus coexpressing HIV-1(CN) gp120 and IL-2","volume":"130","author":"Jiang","year":"2005","journal-title":"J. Virol. Methods"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"e429","DOI":"10.1186\/1743-422X-8-429","article-title":"Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles","volume":"8","author":"Bridge","year":"2011","journal-title":"Virol. J."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"10180","DOI":"10.1128\/JVI.72.12.10180-10188.1998","article-title":"Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus","volume":"72","author":"Kent","year":"1998","journal-title":"J. Virol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4161\/hv.1.6.2342","article-title":"Randomized, placebo-controlled, phase I\/IIa evaluation of the safety and immunogenicity of fowlpox virus expressing HIV gag-pol and interferon-gamma in HIV-1 infected subjects","volume":"1","author":"Emery","year":"2005","journal-title":"Hum. Vaccine"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/01.aids.0000199819.40079.e9","article-title":"A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1","volume":"20","author":"Kelleher","year":"2006","journal-title":"AIDS"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"835","DOI":"10.4161\/hv.6.10.12635","article-title":"An HIV-1 clade A\/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase I\/IIa trial in Thai volunteers at low risk of HIV infection","volume":"6","author":"Hemachandra","year":"2010","journal-title":"Hum. Vaccine"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.vaccine.2010.12.104","article-title":"A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects","volume":"29","author":"Keefer","year":"2011","journal-title":"Vaccine"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1637\/7998-041807-Reg","article-title":"Protection of chickens from Newcastle disease and infectious laryngotracheitis with a recombinant fowlpox virus co-expressing the F, HN genes of Newcastle disease virus and gB gene of infectious laryngotracheitis virus","volume":"52","author":"Sun","year":"2008","journal-title":"Avian Dis."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1128\/jvi.64.4.1441-1450.1990","article-title":"Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens","volume":"64","author":"Taylor","year":"1990","journal-title":"J. Virol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/0378-1135(90)90161-N","article-title":"A fowlpox virus vaccine vector with insertion sites in the terminal repeats: Demonstration of its efficacy using the fusion gene of Newcastle disease virus","volume":"23","author":"Boursnell","year":"1990","journal-title":"Vet. Microbiol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/0264-410X(90)90251-G","article-title":"Recombinant fowlpox viruses inducing protective immunity against Newcastle disease and fowlpox viruses","volume":"8","author":"Ogawa","year":"1990","journal-title":"Vaccine"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0042-6822(90)90165-N","article-title":"Protection of chickens with a recombinant fowlpox virus expressing the Newcastle disease virus hemagglutinin-neuraminidase gene","volume":"179","author":"Edbauer","year":"1990","journal-title":"Virology"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2307\/1591592","article-title":"Antibody response to Newcastle disease virus (NDV) of recombinant fowlpox virus (FPV) expressing a hemagglutinin-neuraminidase of NDV into chickens in the presence of antibody to NDV or FPV","volume":"35","author":"Iritani","year":"1991","journal-title":"Avian Dis."},{"key":"ref_134","first-page":"306","article-title":"Vaccination of chickens with a recombinant fowlpox virus containing the hemagglutinin-neuraminidase gene of Newcastle disease virus under the control of the fowlpox virus thymidine kinase promoter","volume":"58","author":"Nagy","year":"1994","journal-title":"Can. J. Vet. Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0264-410X(97)00295-8","article-title":"Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: Influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses","volume":"16","author":"Karaca","year":"1998","journal-title":"Vaccine"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0264-410X(99)00254-6","article-title":"Embryo vaccination of turkeys against Newcastle disease infection with recombinant fowlpox virus constructs containing interferons as adjuvants","volume":"18","author":"Rautenschlein","year":"1999","journal-title":"Vaccine"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1637\/7398-062105R.1","article-title":"Evaluation of the efficacy of a live fowlpox-vectored infectious laryngotracheitis\/avian encephalomyelitis vaccine against ILT viral challenge","volume":"50","author":"Davison","year":"2006","journal-title":"Avian Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1637\/10345-090312-Reg.1","article-title":"Detection of infectious laryngotracheitis virus antibodies by glycoprotein-specific ELISAs in chickens vaccinated with viral vector vaccines","volume":"57","author":"Godoy","year":"2013","journal-title":"Avian Dis."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1080\/03079457.2011.631983","article-title":"Protection induced by commercially available live-attenuated and recombinant viral vector vaccines against infectious laryngotracheitis virus in broiler chickens","volume":"41","author":"Vagnozzi","year":"2012","journal-title":"Avian Pathol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"7046","DOI":"10.1016\/j.vaccine.2009.09.065","article-title":"Protection of chickens against infectious bronchitis by a recombinant fowlpox virus co-expressing IBV-S1 and chicken IFNgamma","volume":"27","author":"Wang","year":"2009","journal-title":"Vaccine"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.1016\/j.vaccine.2010.09.106","article-title":"Construction and immunogenicity of a recombinant fowlpox vaccine coexpressing S1 glycoprotein of infectious bronchitis virus and chicken IL-18","volume":"28","author":"Chen","year":"2010","journal-title":"Vaccine"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.vaccine.2010.12.102","article-title":"Evaluation of recombinant fowlpox virus expressing infectious bronchitis virus S1 gene and chicken interferon-gamma gene for immune protection against heterologous strains","volume":"29","author":"Shi","year":"2011","journal-title":"Vaccine"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1637\/0005-2086(2002)046[0831:CAISOR]2.0.CO;2","article-title":"Construction and immunogenicity studies of recombinant fowl poxvirus containing the S1 gene of Massachusetts 41 strain of infectious bronchitis virus","volume":"46","author":"Wang","year":"2002","journal-title":"Avian Dis."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1186\/s13567-014-0107-6","article-title":"Immunogenicity and efficacy of fowlpox-vectored and inactivated avian influenza vaccines alone or in a prime-boost schedule in chickens with maternal antibodies","volume":"45","author":"Goutebroze","year":"2014","journal-title":"Vet. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1637\/7624-042706R.1","article-title":"Efficacy of a fowlpox-vectored avian influenza H5 vaccine against Asian H5N1 highly pathogenic avian influenza virus challenge","volume":"51","author":"Bublot","year":"2007","journal-title":"Avian Dis."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.vaccine.2008.11.044","article-title":"Prime-boost vaccination with a fowlpox vector and an inactivated avian influenza vaccine is highly immunogenic in Pekin ducks challenged with Asian H5N1 HPAI","volume":"27","author":"Steensels","year":"2009","journal-title":"Vaccine"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.antiviral.2008.12.002","article-title":"Recombinant fowlpox virus vector-based vaccine completely protects chickens from H5N1 avian influenza virus","volume":"81","author":"Qiao","year":"2009","journal-title":"Antivir. Res."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1637\/8774-033109-ResNote.1","article-title":"High level of protection induced by two fowlpox vector vaccines against a highly pathogenic avian influenza H5N1 challenge in specific-pathogen-free chickens","volume":"54","author":"Bublot","year":"2010","journal-title":"Avian Dis."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/0264-410X(88)90101-6","article-title":"Protective immunity against avian influenza induced by a fowlpox virus recombinant","volume":"6","author":"Taylor","year":"1988","journal-title":"Vaccine"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"6279","DOI":"10.1016\/j.vaccine.2012.08.008","article-title":"The immune response of a recombinant fowlpox virus coexpressing the HA gene of the H5N1 highly pathogenic avian influenza virus and chicken interleukin 6 gene in ducks","volume":"30","author":"Qian","year":"2012","journal-title":"Vaccine"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1016\/j.vaccine.2013.05.039","article-title":"Protection against H7N3 high pathogenicity avian influenza in chickens immunized with a recombinant fowlpox and an inactivated avian influenza vaccines","volume":"31","author":"Bertran","year":"2013","journal-title":"Vaccine"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1016\/j.vaccine.2006.03.006","article-title":"Construction and immunogenicity of recombinant fowlpox vaccines coexpressing HA of AIV H5N1 and chicken IL18","volume":"24","author":"Mingxiao","year":"2006","journal-title":"Vaccine"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1196\/annals.1373.023","article-title":"Development and use of fowlpox vectored vaccines for avian influenza","volume":"1081","author":"Bublot","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"356","DOI":"10.2307\/1591189","article-title":"Protection of chickens against highly pathogenic avian influenza virus (H5N2) by recombinant fowlpox viruses","volume":"35","author":"Beard","year":"1991","journal-title":"Avian Dis."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/0264-410X(91)90055-B","article-title":"Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens","volume":"9","author":"Webster","year":"1991","journal-title":"Vaccine"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2307\/1592246","article-title":"Immunity to Mexican H5N2 avian influenza viruses induced by a fowl pox-H5 recombinant","volume":"40","author":"Webster","year":"1996","journal-title":"Avian Dis."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/S0264-410X(99)00369-2","article-title":"Protection against diverse highly pathogenic H5 avian influenza viruses in chickens immunized with a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene insert","volume":"18","author":"Swayne","year":"2000","journal-title":"Vaccine"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1751-0813.2000.tb10359.x","article-title":"Vaccinating chickens against avian influenza with fowlpox recombinants expressing the H7 haemagglutinin","volume":"78","author":"Boyle","year":"2000","journal-title":"Aust. Vet. J."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1080\/0307945021000070688","article-title":"Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes","volume":"32","author":"Qiao","year":"2003","journal-title":"Avian Pathol."},{"key":"ref_160","first-page":"127","article-title":"Development of a recombinant fowlpox virus vector-based vaccine of H5N1 subtype avian influenza","volume":"124","author":"Qiao","year":"2006","journal-title":"Dev. Biol."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1016\/j.vaccine.2013.06.074","article-title":"Prime-boost vaccination with recombinant H5-fowlpox and Newcastle disease virus vectors affords lasting protection in SPF Muscovy ducks against highly pathogenic H5N1 influenza virus","volume":"31","author":"Niqueux","year":"2013","journal-title":"Vaccine"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1016\/j.vaccine.2006.03.060","article-title":"In ovo DNA immunisation followed by a recombinant fowlpox boost is fully protective to challenge with virulent IBDV","volume":"24","author":"Haygreen","year":"2006","journal-title":"Vaccine"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01310475","article-title":"A recombinant fowlpox virus that expresses the VP2 antigen of infectious bursal disease virus induces protection against mortality caused by the virus","volume":"120","author":"Bayliss","year":"1991","journal-title":"Arch. Virol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/BF01378632","article-title":"Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens","volume":"131","author":"Heine","year":"1993","journal-title":"Arch. Virol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1016\/S0264-410X(00)00133-X","article-title":"Protection from IBDV-induced bursal damage by a recombinant fowlpox vaccine, fpIBD1, is dependent on the titre of challenge virus and chicken genotype","volume":"18","author":"Shaw","year":"2000","journal-title":"Vaccine"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1080\/03079450310001610686","article-title":"Protection from infectious bursal disease virus (IBDV)-induced immunosuppression by immunization with a fowlpox recombinant containing IBDV-VP2","volume":"32","author":"Butter","year":"2003","journal-title":"Avian Pathol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1128\/jvi.66.3.1409-1413.1992","article-title":"Protection against Marek\u2019s disease by a fowlpox virus recombinant expressing the glycoprotein B of Marek\u2019s disease virus","volume":"66","author":"Nazerian","year":"1992","journal-title":"J. Virol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0165-2427(97)00159-1","article-title":"Cytotoxic T lymphocyte response in chickens immunized with a recombinant fowlpox virus expressing Marek\u2019s disease herpesvirus glycoprotein B","volume":"62","author":"Omar","year":"1998","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_169","first-page":"201","article-title":"A recombinant fowlpox virus vaccine expressing glycoprotein B gene from CVI988\/Rispens strain of MDV: Protection studies in different chickens","volume":"43","author":"Liu","year":"1999","journal-title":"Acta Virol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1637\/6073","article-title":"Protection and synergism by recombinant fowl pox vaccines expressing multiple genes from Marek\u2019s disease virus","volume":"47","author":"Lee","year":"2003","journal-title":"Avian Dis."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1637\/7083","article-title":"The efficacy of recombinant fowlpox vaccine protection against Marek\u2019s disease: Its dependence on chicken line and B haplotype","volume":"48","author":"Lee","year":"2004","journal-title":"Avian Dis."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/0264-410X(91)90152-V","article-title":"Efficacy studies on a canarypox-rabies recombinant virus","volume":"9","author":"Taylor","year":"1991","journal-title":"Vaccine"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"e190","DOI":"10.1186\/1479-5876-9-190","article-title":"Construction and characterisation of a recombinant fowlpox virus that expresses the human papilloma virus L1 protein","volume":"9","author":"Zanotto","year":"2011","journal-title":"J. Transl. Med."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jviromet.2009.01.021","article-title":"Construction and characterization of recombinant fowlpox viruses expressing human papilloma virus E6 and E7 oncoproteins","volume":"158","author":"Pozzi","year":"2009","journal-title":"J. Virol. Methods"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.jviromet.2006.05.019","article-title":"Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus","volume":"136","author":"Zheng","year":"2006","journal-title":"J. Virol. Methods"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.vetimm.2007.06.029","article-title":"Immune responses of swine inoculated with a recombinant fowlpox virus co-expressing P12A and 3C of FMDV and swine IL-18","volume":"121","author":"Ma","year":"2008","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_177","first-page":"59","article-title":"Construction of recombinant fowlpox virus expressing E0 gene of classical swine fever virus shimen strain and the animal immunity experiment","volume":"24","author":"Wang","year":"2008","journal-title":"Bing Du Xue Bao"},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"7436","DOI":"10.1016\/j.vaccine.2010.08.091","article-title":"The development of persistent duck hepatitis B virus infection can be prevented using antiviral therapy combined with DNA or recombinant fowlpoxvirus vaccines","volume":"28","author":"Feng","year":"2010","journal-title":"Vaccine"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1016\/j.vaccine.2007.03.010","article-title":"Immune responses of pigs inoculated with a recombinant fowlpox virus coexpressing GP5\/GP3 of porcine reproductive and respiratory syndrome virus and swine IL-18","volume":"25","author":"Shen","year":"2007","journal-title":"Vaccine"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/0264-410X(94)90319-0","article-title":"Protection against turkey rhinotracheitis pneumovirus (TRTV) induced by a fowlpox virus recombinant expressing the TRTV fusion glycoprotein (F)","volume":"12","author":"Qingzhong","year":"1994","journal-title":"Vaccine"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2460\/ajvr.1997.58.06.590","article-title":"Protective vaccination of ferrets against canine distemper with recombinant pox virus vaccines expressing the H or F genes of rinderpest virus","volume":"58","author":"Jones","year":"1997","journal-title":"Am. J. Vet. Res."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2307\/1592613","article-title":"Protection of turkeys from hemorrhagic enteritis with a recombinant fowl poxvirus expressing the native hexon of hemorrhagic enteritis virus","volume":"43","author":"Cardona","year":"1999","journal-title":"Avian Dis."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/0264-410X(90)90243-F","article-title":"Fowlpox virus recombinant encoding the measles virus fusion protein: Protection of mice against fatal measles encephalitis","volume":"8","author":"Wild","year":"1990","journal-title":"Vaccine"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.virusres.2013.09.016","article-title":"Systemically administered DNA and fowlpox recombinants expressing four vaccinia virus genes although immunogenic do not protect mice against the highly pathogenic IHD-J vaccinia strain","volume":"178","author":"Bissa","year":"2013","journal-title":"Virus Res."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1186\/1479-5876-11-95","article-title":"L1R, A27L, A33R and B5R vaccinia virus genes expressed by fowlpox recombinants as putative novel orthopoxvirus vaccines","volume":"11","author":"Pacchioni","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.vetmic.2013.03.015","article-title":"Evaluation of the pathogenicity of avipoxvirus strains isolated from wild birds in New Zealand and the efficacy of a fowlpox vaccine in passerines","volume":"165","author":"Ha","year":"2013","journal-title":"Vet. Microbiol."},{"key":"ref_187","first-page":"388","article-title":"Oral fowlpox vaccination in chickens","volume":"39","author":"Jieyuan","year":"1992","journal-title":"Zentralbl. Veterinarmed. B"},{"key":"ref_188","first-page":"522","article-title":"Vaccination of chickens with live fowl pox (FP) vaccine in oil","volume":"40","author":"Peleg","year":"1993","journal-title":"Zentralbl. Veterinarmed. B"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.3382\/ps.2009-00447","article-title":"A safety assessment of a fowlpox-vectored Mycoplasma gallisepticum vaccine in chickens","volume":"89","author":"Zhang","year":"2010","journal-title":"Poult. Sci."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.exppara.2007.12.009","article-title":"Eimeria tenella: Construction of a recombinant fowlpox virus expressing rhomboid gene and its protective efficacy against homologous infection","volume":"119","author":"Yang","year":"2008","journal-title":"Exp. Parasitol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"6402","DOI":"10.1016\/j.vaccine.2012.08.018","article-title":"Effects of route and coadministration of recombinant raccoon poxviruses on immune responses and protection against highly pathogenic avian influenza in mice","volume":"30","author":"Brewoo","year":"2012","journal-title":"Vaccine"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"5502","DOI":"10.1128\/IAI.72.9.5502-5505.2004","article-title":"Protection of black-tailed prairie dogs (Cynomys ludovicianus) against plague after voluntary consumption of baits containing recombinant raccoon poxvirus vaccine","volume":"72","author":"Mencher","year":"2004","journal-title":"Infect. Immun."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1016\/S0264-410X(02)00557-1","article-title":"Recombinant raccoon pox vaccine protects mice against lethal plague","volume":"21","author":"Osorio","year":"2003","journal-title":"Vaccine"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.vaccine.2009.10.043","article-title":"Further development of raccoon poxvirus-vectored vaccines against plague (Yersinia pestis)","volume":"28","author":"Rocke","year":"2009","journal-title":"Vaccine"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1089\/vbz.2009.0050","article-title":"Consumption of baits containing raccoon pox-based plague vaccines protects black-tailed prairie dogs (Cynomys ludovicianus)","volume":"10","author":"Rocke","year":"2010","journal-title":"Vector Borne Zoonotic Dis."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"930","DOI":"10.7589\/0090-3558-44.4.930","article-title":"Immunization of black-tailed prairie dog against plague through consumption of vaccine-laden baits","volume":"44","author":"Rocke","year":"2008","journal-title":"J. Wildl. Dis."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/BF01309757","article-title":"Raccoon poxvirus rabies virus glycoprotein recombinant vaccine in sheep","volume":"133","author":"DeMartini","year":"1993","journal-title":"Arch. Virol."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"681","DOI":"10.7589\/0090-3558-27.4.681","article-title":"Oral vaccination of skunks with raccoon poxvirus recombinants expressing the rabies glycoprotein or the nucleoprotein","volume":"27","author":"Fekadu","year":"1991","journal-title":"J. Wildl. Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S0264-410X(97)00062-5","article-title":"Raccoon poxvirus live recombinant feline panleukopenia virus VP2 and rabies virus glycoprotein bivalent vaccine","volume":"15","author":"Hu","year":"1997","journal-title":"Vaccine"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/10611860410001670062","article-title":"Raccoon poxvirus as a mucosal vaccine vector for domestic cats","volume":"11","author":"Osorio","year":"2003","journal-title":"J. Drug Target"},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1128\/jvi.67.10.6080-6086.1993","article-title":"Rabies virus antinucleoprotein antibody protects against rabies virus challenge in vivo and inhibits rabies virus replication in vitro","volume":"67","author":"Lodmell","year":"1993","journal-title":"J. Virol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1006\/viro.1996.0186","article-title":"Raccoon poxvirus feline panleukopenia virus VP2 recombinant protects cats against FPV challenge","volume":"218","author":"Hu","year":"1996","journal-title":"Virology"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/978-1-4615-1899-0_36","article-title":"Protection of cats from infectious peritonitis by vaccination with a recombinant raccoon poxvirus expressing the nucleocapsid gene of feline infectious peritonitis virus","volume":"380","author":"Wasmoen","year":"1995","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"e83802","DOI":"10.1371\/journal.pone.0083802","article-title":"New Orf virus (Parapoxvirus) recombinant expressing H5 hemagglutinin protects mice against H5N1 and H1N1 influenza A virus","volume":"8","author":"Rohde","year":"2013","journal-title":"PLOS ONE"},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1128\/JVI.02470-12","article-title":"A new rabies vaccine based on a recombinant ORF virus (parapoxvirus) expressing the rabies virus glycoprotein","volume":"87","author":"Amann","year":"2013","journal-title":"J. Virol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"6256","DOI":"10.1016\/j.vaccine.2006.05.078","article-title":"Prime-boost immunization using DNA vaccine and recombinant Orf virus protects pigs against Pseudorabies virus (Herpes suid 1)","volume":"24","author":"Dory","year":"2006","journal-title":"Vaccine"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S0264-410X(02)00736-3","article-title":"DNA vaccination of neonate piglets in the face of maternal immunity induces humoral memory and protection against a virulent pseudorabies virus challenge","volume":"21","author":"Fischer","year":"2003","journal-title":"Vaccine"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.vaccine.2009.12.004","article-title":"Comparison of different prime-boost regimes with DNA and recombinant Orf virus based vaccines expressing glycoprotein D of pseudorabies virus in pigs","volume":"28","author":"Rijsewijk","year":"2010","journal-title":"Vaccine"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1128\/JVI.79.1.314-325.2005","article-title":"Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant","volume":"79","author":"Henkel","year":"2005","journal-title":"J. Virol."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"9256","DOI":"10.1016\/j.vaccine.2011.09.121","article-title":"A new recombinant Orf virus (ORFV, Parapoxvirus) protects rabbits against lethal infection with rabbit hemorrhagic disease virus (RHDV)","volume":"29","author":"Rohde","year":"2011","journal-title":"Vaccine"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1016\/j.vaccine.2007.05.035","article-title":"Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2)","volume":"25","author":"Voigt","year":"2007","journal-title":"Vaccine"},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1128\/JVI.77.2.1571-1577.2003","article-title":"Development of a dual recombinant vaccine to protect small ruminants against peste-des-petits-ruminants virus and capripoxvirus infections","volume":"77","author":"Berhe","year":"2003","journal-title":"J. Virol."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1016\/j.vaccine.2014.05.025","article-title":"Protective efficacy of a single immunization with capripoxvirus-vectored recombinant peste des petits ruminants vaccines in presence of pre-existing immunity","volume":"32","author":"Caufour","year":"2014","journal-title":"Vaccine"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"4742","DOI":"10.1016\/j.vaccine.2010.04.102","article-title":"A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep","volume":"28","author":"Chen","year":"2010","journal-title":"Vaccine"},{"key":"ref_215","first-page":"113","article-title":"Control of peste des petits ruminants: Classical and new generation vaccines","volume":"114","author":"Diallo","year":"2003","journal-title":"Dev. Biol."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1749-6632.2002.tb04356.x","article-title":"Goat immune response to capripox vaccine expressing the hemagglutinin protein of peste des petits ruminants","volume":"969","author":"Diallo","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"6058","DOI":"10.1016\/j.vaccine.2006.05.021","article-title":"A bivalent vaccine against goat pox and Peste des Petits ruminants induces protective immune response in goats","volume":"24","author":"Hosamani","year":"2006","journal-title":"Vaccine"},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/0264-410X(95)80008-2","article-title":"Protection of goats against peste des petits ruminants with recombinant capripoxviruses expressing the fusion and haemagglutinin protein genes of rinderpest virus","volume":"13","author":"Romero","year":"1995","journal-title":"Vaccine"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1099\/vir.0.067835-0","article-title":"The novel capripoxvirus vector lumpy skin disease virus efficiently boosts modified vaccinia Ankara human immunodeficiency virus responses in rhesus macaques","volume":"95","author":"Burgers","year":"2014","journal-title":"J. Gen. Virol."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/1743-422X-8-265","article-title":"A novel candidate HIV vaccine vector based on the replication deficient Capripoxvirus, Lumpy skin disease virus (LSDV)","volume":"8","author":"Shen","year":"2011","journal-title":"Virol. J."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1128\/CVI.00220-10","article-title":"Protection of sheep against Rift Valley fever virus and sheep poxvirus with a recombinant capripoxvirus vaccine","volume":"17","author":"Soi","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"7181","DOI":"10.1016\/j.vaccine.2006.06.041","article-title":"Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever","volume":"24","author":"Wallace","year":"2006","journal-title":"Vaccine"},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1017\/S0950268896007200","article-title":"Trial of a capripoxvirus-rinderpest recombinant vaccine in African cattle","volume":"118","author":"Ngichabe","year":"1997","journal-title":"Epidemiol. Infect."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1017\/S0950268801006513","article-title":"Long term immunity in African cattle vaccinated with a recombinant capripox-rinderpest virus vaccine","volume":"128","author":"Ngichabe","year":"2002","journal-title":"Epidemiol. Infect."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1006\/viro.1994.1548","article-title":"Recombinant capripoxvirus expressing the hemagglutinin protein gene of rinderpest virus: Protection of cattle against rinderpest and lumpy skin disease viruses","volume":"204","author":"Romero","year":"1994","journal-title":"Virology"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/0264-410X(93)90258-Y","article-title":"Single capripoxvirus recombinant vaccine for the protection of cattle against rinderpest and lumpy skin disease","volume":"11","author":"Romero","year":"1993","journal-title":"Vaccine"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1136\/vr.135.7.152","article-title":"Protection of cattle against rinderpest and lumpy skin disease with a recombinant capripoxvirus expressing the fusion protein gene of rinderpest virus","volume":"135","author":"Romero","year":"1994","journal-title":"Vet. Rec."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"6774","DOI":"10.1016\/j.vaccine.2007.06.052","article-title":"Recombinant capripoxviruses expressing proteins of bluetongue virus: Evaluation of immune responses and protection in small ruminants","volume":"25","author":"Perrin","year":"2007","journal-title":"Vaccine"},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1006\/viro.1996.0306","article-title":"Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge","volume":"220","author":"Romero","year":"1996","journal-title":"Virology"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/S0264-410X(02)00203-7","article-title":"Immunogenicity of a recombinant lumpy skin disease virus (neethling vaccine strain) expressing the rabies virus glycoprotein in cattle","volume":"20","author":"Aspden","year":"2002","journal-title":"Vaccine"},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"6307","DOI":"10.1016\/j.vaccine.2012.07.082","article-title":"Construction and immunogenicity of recombinant swinepox virus expressing capsid protein of PCV2","volume":"30","author":"Lin","year":"2012","journal-title":"Vaccine"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.vetmic.2014.03.018","article-title":"A novel vaccine against Porcine circovirus type 2 (PCV2) and Streptococcus equi ssp. zooepidemicus (SEZ) co-infection","volume":"171","author":"Lin","year":"2014","journal-title":"Vet. Microbiol."},{"key":"ref_233","first-page":"144","article-title":"First insights into the protective effects of a recombinant swinepox virus expressing truncated MRP of Streptococcus suis type 2 in mice","volume":"125","author":"Huang","year":"2012","journal-title":"Berl. Munch. Tierarztl. Wochenschr."},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.vetmic.2012.11.026","article-title":"Immune responses and protective efficacy of a recombinant swinepox virus co-expressing HA1 genes of H3N2 and H1N1 swine influenza virus in mice and pigs","volume":"162","author":"Xu","year":"2013","journal-title":"Vet. Microbiol."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00705-012-1539-9","article-title":"Protection of guinea pigs by vaccination with a recombinant swinepox virus co-expressing HA1 genes of swine H1N1 and H3N2 influenza viruses","volume":"158","author":"Xu","year":"2013","journal-title":"Arch. Virol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.virusres.2012.04.014","article-title":"Immune responses and protection efficacy of a recombinant swinepox virus expressing HA1 against swine H3N2 influenza virus in mice and pigs","volume":"167","author":"Xu","year":"2012","journal-title":"Virus Res."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.vaccine.2011.12.108","article-title":"Myxomavirus as a vector for the immunisation of sheep: Protection study against challenge with bluetongue virus","volume":"30","author":"Top","year":"2012","journal-title":"Vaccine"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1016\/j.vaccine.2005.05.038","article-title":"Potential for broad-spectrum protection against feline calicivirus using an attenuated myxoma virus expressing a chimeric FCV capsid protein","volume":"23","author":"McCabe","year":"2005","journal-title":"Vaccine"},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/S0264-410X(02)00186-X","article-title":"Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein","volume":"20","author":"McCabe","year":"2002","journal-title":"Vaccine"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/S0042-6822(03)00324-6","article-title":"Antibody response in the female rabbit reproductive tract to influenza haemagglutinin encoded by a recombinant myxoma virus","volume":"313","author":"Gu","year":"2003","journal-title":"Virology"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/0264-410X(95)00113-F","article-title":"Myxoma virus as a vaccine vector for rabbits: Antibody levels to influenza virus haemagglutinin presented by a recombinant myxoma virus","volume":"13","author":"Kerr","year":"1995","journal-title":"Vaccine"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1128\/JVI.74.3.1114-1123.2000","article-title":"Horizontal transmissible protection against myxomatosis and rabbit hemorrhagic disease by using a recombinant myxoma virus","volume":"74","author":"Barcena","year":"2000","journal-title":"J. Virol."},{"key":"ref_243","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1128\/jvi.70.8.5061-5066.1996","article-title":"Protection against myxomatosis and rabbit viral hemorrhagic disease with recombinant myxoma viruses expressing rabbit hemorrhagic disease virus capsid protein","volume":"70","author":"Bertagnoli","year":"1996","journal-title":"J. Virol."},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0264-410X(00)00183-3","article-title":"Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease","volume":"19","author":"Torres","year":"2000","journal-title":"Vaccine"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1016\/S0264-410X(01)00184-0","article-title":"First field trial of a transmissible recombinant vaccine against myxomatosis and rabbit hemorrhagic disease","volume":"19","author":"Torres","year":"2001","journal-title":"Vaccine"},{"key":"ref_246","unstructured":"Hashizume, S.C. (1975). Special edition future of vaccination: Everything about attenuated vaccines. Basics of new attenuated vaccine strain LC16m8. Clin Virus, 229\u2013235."},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"7009","DOI":"10.1016\/j.vaccine.2006.03.087","article-title":"LC16m8: An attenuated smallpox vaccine","volume":"24","author":"Kenner","year":"2006","journal-title":"Vaccine"},{"key":"ref_248","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/BF01314664","article-title":"Comparative studies of several vaccinia virus strains by intrathalamic inoculation into cynomolgus monkeys","volume":"53","author":"Morita","year":"1977","journal-title":"Arch. Virol."},{"key":"ref_249","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/0042-6822(91)90480-Y","article-title":"Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins","volume":"181","author":"Funahashi","year":"1991","journal-title":"Virology"},{"key":"ref_250","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1016\/j.vaccine.2005.03.029","article-title":"Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge","volume":"24","author":"Empig","year":"2006","journal-title":"Vaccine"},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1128\/CVI.00040-09","article-title":"Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model","volume":"16","author":"Meseda","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_252","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/infdis\/jiq162","article-title":"Smallpox vaccine safety is dependent on T cells and not B cells","volume":"203","author":"Gordon","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"5179","DOI":"10.1128\/JVI.02642-05","article-title":"LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox","volume":"80","author":"Saijo","year":"2006","journal-title":"J. Virol."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1128\/CVI.00199-14","article-title":"Safety of attenuated smallpox vaccine LC16m8 in immunodeficient mice","volume":"21","author":"Yokote","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/infdis\/jir527","article-title":"Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults","volume":"204","author":"Kennedy","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jama.2009.289","article-title":"Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8","volume":"301","author":"Saito","year":"2009","journal-title":"JAMA"},{"key":"ref_257","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.1073\/pnas.0406671102","article-title":"Genetically stable and fully effective smallpox vaccine strain constructed from highly attenuated vaccinia LC16m8","volume":"102","author":"Kidokoro","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.virol.2004.05.004","article-title":"Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin","volume":"325","author":"Bell","year":"2004","journal-title":"Virology"},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1099\/vir.0.034207-0","article-title":"Serological responses in humans to the smallpox vaccine LC16m8","volume":"92","author":"Johnson","year":"2011","journal-title":"J. Gen. Virol."},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clim.2005.12.007","article-title":"Robust HIV-specific immune responses were induced by DNA vaccine prime followed by attenuated recombinant vaccinia virus (LC16m8 strain) boost","volume":"119","author":"Shinoda","year":"2006","journal-title":"Clin. Immunol."},{"key":"ref_261","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.vaccine.2006.08.039","article-title":"SARS-CoV spike protein-expressing recombinant vaccinia virus efficiently induces neutralizing antibodies in rabbits pre-immunized with vaccinia virus","volume":"25","author":"Kitabatake","year":"2007","journal-title":"Vaccine"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/192381a0","article-title":"A new mutant of dermovaccinia virus","volume":"192","author":"Tagaya","year":"1961","journal-title":"Nature"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1006\/viro.2002.1622","article-title":"Structural analysis of vaccinia virus DIs strain: Application as a new replication-deficient viral vector","volume":"302","author":"Ishii","year":"2002","journal-title":"Virology"},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"9842","DOI":"10.1128\/JVI.78.18.9842-9853.2004","article-title":"A consecutive priming-boosting vaccination of mice with simian immunodeficiency virus (SIV) gag\/pol DNA and recombinant vaccinia virus strain DIs elicits effective anti-SIV immunity","volume":"78","author":"Someya","year":"2004","journal-title":"J. Virol."},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-3083.2008.02168.x","article-title":"Mucosal administration of completely non-replicative vaccinia virus recombinant Dairen I strain elicits effective mucosal and systemic immunity","volume":"68","author":"Yoshino","year":"2008","journal-title":"Scand. J. Immunol."},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1348-0421.2006.tb03867.x","article-title":"Recombinant vaccinia DIs expressing simian immunodeficiency virus gag and pol in mammalian cells induces efficient cellular immunity as a safe immunodeficiency virus vaccine candidate","volume":"50","author":"Okamura","year":"2006","journal-title":"Microbiol. Immunol."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.4049\/jimmunol.176.3.1784","article-title":"Induction of positive cellular and humoral immune responses by a prime-boost vaccine encoded with simian immunodeficiency virus gag\/pol","volume":"176","author":"Someya","year":"2006","journal-title":"J. Immunol."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0168-1702(89)90042-7","article-title":"Characterization of vaccinia virus deletion mutants isolated from persistently infected Friend erythroleukemia cells","volume":"12","author":"Lai","year":"1989","journal-title":"Virus Res."},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1128\/jvi.61.8.2642-2647.1987","article-title":"Virus attenuation and identification of structural proteins of vaccinia virus that are selectively modified during virus persistence","volume":"61","author":"Paez","year":"1987","journal-title":"J. Virol."},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1073\/pnas.82.10.3365","article-title":"Generation of a dominant 8-MDa deletion at the left terminus of vaccinia virus DNA","volume":"82","author":"Paez","year":"1985","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_271","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1128\/JVI.03013-12","article-title":"Attenuated and replication-competent vaccinia virus strains M65 and M101 with distinct biology and immunogenicity as potential vaccine candidates against pathogens","volume":"87","author":"Gomez","year":"2013","journal-title":"J. Virol."},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1128\/iai.61.8.3351-3359.1993","article-title":"Recombinant vaccinia viruses expressing GP46\/M-2 protect against Leishmania infection","volume":"61","author":"Rodriguez","year":"1993","journal-title":"Infect. Immun."},{"key":"ref_273","first-page":"283","article-title":"An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author\u2019s transl)","volume":"230","author":"Hanichen","year":"1975","journal-title":"Zentralbl. Bakteriol. Orig. A"},{"key":"ref_274","first-page":"375","article-title":"The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author\u2019s transl)","volume":"167","author":"Mayr","year":"1978","journal-title":"Zentralbl. Bakteriol. B"},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1006\/viro.1998.9123","article-title":"The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses","volume":"244","author":"Antoine","year":"1998","journal-title":"Virology"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1099\/0022-1317-72-5-1031","article-title":"Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence","volume":"72","author":"Meyer","year":"1991","journal-title":"J. Gen. Virol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1099\/0022-1317-79-5-1159","article-title":"Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine","volume":"79","author":"Blanchard","year":"1998","journal-title":"J. Gen. Virol."},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/viro.1998.9397","article-title":"Marker rescue of the host range restriction defects of modified vaccinia virus Ankara","volume":"251","author":"Wyatt","year":"1998","journal-title":"Virology"},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"10847","DOI":"10.1073\/pnas.89.22.10847","article-title":"Nonreplicating vaccinia vector efficiently expresses recombinant genes","volume":"89","author":"Sutter","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_280","first-page":"104","article-title":"Virulence and immunogenicity of a modified vaccinia virus (strain MVA) (author\u2019s transl)","volume":"144","author":"Huber","year":"1972","journal-title":"Z. Immunitatsforsch. Exp. Klin. Immunol."},{"key":"ref_281","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/421266","article-title":"Modified vaccinia Ankara: Potential as an alternative smallpox vaccine","volume":"38","author":"McCurdy","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_282","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1128\/JVI.01706-07","article-title":"Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax","volume":"82","author":"Davies","year":"2008","journal-title":"J. Virol."},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"4590","DOI":"10.1073\/pnas.0401165101","article-title":"Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge","volume":"101","author":"Wyatt","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.virol.2007.02.041","article-title":"Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate","volume":"366","author":"Earl","year":"2007","journal-title":"Virology"},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/nature02331","article-title":"Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox","volume":"428","author":"Earl","year":"2004","journal-title":"Nature"},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"10889","DOI":"10.1073\/pnas.0804985105","article-title":"Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus","volume":"105","author":"Earl","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1016\/j.vaccine.2007.10.017","article-title":"Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge","volume":"25","author":"Frey","year":"2007","journal-title":"Vaccine"},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.virol.2005.06.002","article-title":"Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model","volume":"339","author":"Meseda","year":"2005","journal-title":"Virology"},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1099\/vir.0.055921-0","article-title":"Vaccinia virus immune evasion: Mechanisms, virulence and immunogenicity","volume":"94","author":"Smith","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_290","doi-asserted-by":"crossref","first-page":"e1000480","DOI":"10.1371\/journal.ppat.1000480","article-title":"Innate immune sensing of modified vaccinia virus Ankara (MVA) is mediated by TLR2-TLR6, MDA-5 and the NALP3 inflammasome","volume":"5","author":"Delaloye","year":"2009","journal-title":"PLOS Pathog."},{"key":"ref_291","doi-asserted-by":"crossref","first-page":"8141","DOI":"10.1128\/JVI.00749-10","article-title":"Selective induction of host genes by MVA-B, a candidate vaccine against HIV\/AIDS","volume":"84","author":"Guerra","year":"2010","journal-title":"J. Virol."},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1128\/JVI.01884-08","article-title":"Modified vaccinia virus ankara triggers chemotaxis of monocytes and early respiratory immigration of leukocytes by induction of CCL2 expression","volume":"83","author":"Lehmann","year":"2009","journal-title":"J. Virol."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1089\/aid.2006.0226","article-title":"Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART","volume":"23","author":"Cosma","year":"2007","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"e54407","DOI":"10.1371\/journal.pone.0054407","article-title":"Prospective surveillance for cardiac adverse events in healthy adults receiving modified vaccinia Ankara vaccines: A systematic review","volume":"8","author":"Elizaga","year":"2013","journal-title":"PLOS ONE"},{"key":"ref_295","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.vaccine.2006.10.047","article-title":"Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naive and vaccinia-immune individuals","volume":"25","author":"Parrino","year":"2007","journal-title":"Vaccine"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1086\/651560","article-title":"Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax","volume":"201","author":"Seaman","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1186\/1476-9433-4-2","article-title":"The Future of Smallpox Vaccination: Is MVA the key?","volume":"4","author":"Slifka","year":"2005","journal-title":"Med. Immunol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.vaccine.2005.11.022","article-title":"Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine","volume":"24","author":"Vollmar","year":"2006","journal-title":"Vaccine"},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/j.vaccine.2009.11.030","article-title":"A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE","volume":"28","author":"Vollmar","year":"2010","journal-title":"Vaccine"},{"key":"ref_300","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1016\/j.vaccine.2014.08.022","article-title":"Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis","volume":"32","author":"Perona","year":"2014","journal-title":"Vaccine"},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.3390\/v6072735","article-title":"Modified vaccinia virus ankara (MVA) as production platform for vaccines against influenza and other viral respiratory diseases","volume":"6","author":"Altenburg","year":"2014","journal-title":"Viruses"},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.4161\/hv.21689","article-title":"Therapeutic vaccination to treat chronic infectious diseases: Current clinical developments using MVA-based vaccines","volume":"8","author":"Boukhebza","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1016\/j.vaccine.2013.03.021","article-title":"Recombinant MVA vaccines: Dispelling the myths","volume":"31","author":"Cottingham","year":"2013","journal-title":"Vaccine"},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"4241","DOI":"10.1016\/j.vaccine.2013.03.020","article-title":"Clinical development of Modified Vaccinia virus Ankara vaccines","volume":"31","author":"Gilbert","year":"2013","journal-title":"Vaccine"},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2174\/156652311795684731","article-title":"MVA and NYVAC as vaccines against emergent infectious diseases and cancer","volume":"11","author":"Gomez","year":"2011","journal-title":"Curr. Gene Ther."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4161\/hv.20778","article-title":"Poxvirus vectors as HIV\/AIDS vaccines in humans","volume":"8","author":"Gomez","year":"2012","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1586\/14760584.2013.845531","article-title":"Clinical applications of attenuated MVA poxvirus strain","volume":"12","author":"Gomez","year":"2013","journal-title":"Expert Rev. Vaccines"},{"key":"ref_308","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1016\/j.vaccine.2013.06.073","article-title":"Poxvirus vectors","volume":"31","author":"Kreijtz","year":"2013","journal-title":"Vaccine"},{"key":"ref_309","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.vaccine.2013.03.016","article-title":"Protective efficacy of Modified Vaccinia virus Ankara in preclinical studies","volume":"31","author":"Volz","year":"2013","journal-title":"Vaccine"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1586\/erv.11.79","article-title":"Vaccinia viruses: Vaccines against smallpox and vectors against infectious diseases and tumors","volume":"10","author":"Walsh","year":"2011","journal-title":"Expert Rev. Vaccines"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1086\/651561","article-title":"Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): Effect of dose and route of administration","volume":"201","author":"Wilck","year":"2010","journal-title":"J. Infect. Dis."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"e78289","DOI":"10.1371\/journal.pone.0078289","article-title":"A phase I randomized clinical trial of candidate human immunodeficiency virus type 1 vaccine MVA.HIVA administered to Gambian infants","volume":"8","author":"Afolabi","year":"2013","journal-title":"PLOS ONE"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/aid.2013.0149","article-title":"Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees","volume":"30","author":"Nilsson","year":"2014","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"e55831","DOI":"10.1371\/journal.pone.0055831","article-title":"Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: A phase I randomised Trial in HIV-uninfected Indian volunteers","volume":"8","author":"Mehendale","year":"2013","journal-title":"PLOS ONE"},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"e8816","DOI":"10.1371\/journal.pone.0008816","article-title":"Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B\u2019\/C candidate vaccine","volume":"5","author":"Vasan","year":"2010","journal-title":"PLOS ONE"},{"key":"ref_316","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/infdis\/jiu003","article-title":"Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles","volume":"210","author":"Goepfert","year":"2014","journal-title":"J. Infect. Dis."},{"key":"ref_317","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/CVI.00038-12","article-title":"DNA and modified vaccinia virus Ankara vaccines encoding multiple cytotoxic and helper T-lymphocyte epitopes of human immunodeficiency virus type 1 (HIV-1) are safe but weakly immunogenic in HIV-1-uninfected, vaccinia virus-naive adults","volume":"19","author":"Gorse","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_318","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/gt.2010.90","article-title":"MVA-nef induces HIV-1-specific polyfunctional and proliferative T-cell responses revealed by the combination of short- and long-term immune assays","volume":"17","author":"Kutscher","year":"2010","journal-title":"Gene Ther."},{"key":"ref_319","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/mt.2013.162","article-title":"Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses","volume":"22","author":"Antrobus","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_320","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1016\/S1473-3099(14)70963-6","article-title":"Safety and immunogenicity of a modified-vaccinia-virus-Ankara-based influenza A H5N1 vaccine: A randomised, double-blind phase 1\/2a clinical trial","volume":"14","author":"Kreijtz","year":"2014","journal-title":"Lancet Infect. Dis."},{"key":"ref_321","doi-asserted-by":"crossref","first-page":"e14626","DOI":"10.1371\/journal.pone.0014626","article-title":"Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection","volume":"6","author":"Cavenaugh","year":"2011","journal-title":"PLOS ONE"},{"key":"ref_322","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1128\/JVI.01505-07","article-title":"Rational design of a multiepitope vaccine encoding T-lymphocyte epitopes for treatment of chronic hepatitis B virus infections","volume":"82","author":"Depla","year":"2008","journal-title":"J. Virol."},{"key":"ref_323","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1053\/j.gastro.2014.03.007","article-title":"Efficacy of immunotherapy with TG4040, peg-interferon, and ribavirin in a Phase 2 study of patients with chronic HCV infection","volume":"147","author":"Habersetzer","year":"2014","journal-title":"Gastroenterology"},{"key":"ref_324","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1093\/infdis\/jit267","article-title":"A heterologous prime\/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus","volume":"208","author":"Fournillier","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_325","doi-asserted-by":"crossref","first-page":"3917","DOI":"10.1016\/j.vaccine.2004.04.005","article-title":"Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins","volume":"22","author":"Abraham","year":"2004","journal-title":"Vaccine"},{"key":"ref_326","doi-asserted-by":"crossref","first-page":"7282","DOI":"10.1128\/JVI.03246-12","article-title":"High, broad, polyfunctional, and durable T cell immune responses induced in mice by a novel hepatitis C virus (HCV) vaccine candidate (MVA-HCV) based on modified vaccinia virus Ankara expressing the nearly full-length HCV genome","volume":"87","author":"Gomez","year":"2013","journal-title":"J. Virol."},{"key":"ref_327","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1128\/JVI.03418-13","article-title":"A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection","volume":"88","author":"Cepeda","year":"2014","journal-title":"J. Virol."},{"key":"ref_328","doi-asserted-by":"crossref","first-page":"e2970","DOI":"10.1371\/journal.pntd.0002970","article-title":"A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice","volume":"8","author":"Chu","year":"2014","journal-title":"PLOS Negl. Trop. Dis."},{"key":"ref_329","doi-asserted-by":"crossref","first-page":"e3101","DOI":"10.1371\/journal.pntd.0003101","article-title":"Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge","volume":"8","author":"Volz","year":"2014","journal-title":"PLOS Negl. Trop. Dis."},{"key":"ref_330","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1016\/S0264-410X(00)00121-3","article-title":"Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge","volume":"18","author":"Men","year":"2000","journal-title":"Vaccine"},{"key":"ref_331","doi-asserted-by":"crossref","first-page":"2972","DOI":"10.1016\/j.vaccine.2014.03.093","article-title":"An intact signal peptide on dengue virus E protein enhances immunogenicity for CD8(+) T cells and antibody when expressed from modified vaccinia Ankara","volume":"32","author":"Quinan","year":"2014","journal-title":"Vaccine"},{"key":"ref_332","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1038\/nm.3702","article-title":"Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge","volume":"20","author":"Stanley","year":"2014","journal-title":"Nat. Med."},{"key":"ref_333","doi-asserted-by":"crossref","first-page":"e91516","DOI":"10.1371\/journal.pone.0091516","article-title":"A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model","volume":"9","author":"Buttigieg","year":"2014","journal-title":"PLOS ONE"},{"key":"ref_334","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s00253-007-1073-y","article-title":"Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus","volume":"76","author":"Ba","year":"2007","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"ref_335","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1128\/JVI.79.5.2678-2688.2005","article-title":"Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region","volume":"79","author":"Chen","year":"2005","journal-title":"J. Virol."},{"key":"ref_336","doi-asserted-by":"crossref","first-page":"6641","DOI":"10.1073\/pnas.0401939101","article-title":"Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice","volume":"101","author":"Bisht","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_337","doi-asserted-by":"crossref","first-page":"e4180","DOI":"10.1371\/journal.pone.0004180","article-title":"A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination","volume":"4","author":"Huang","year":"2009","journal-title":"PLOS ONE"},{"key":"ref_338","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/j.vaccine.2005.01.033","article-title":"Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets","volume":"23","author":"Czub","year":"2005","journal-title":"Vaccine"},{"key":"ref_339","doi-asserted-by":"crossref","first-page":"6678","DOI":"10.1016\/j.vaccine.2008.09.006","article-title":"A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus","volume":"26","author":"Schulze","year":"2008","journal-title":"Vaccine"},{"key":"ref_340","doi-asserted-by":"crossref","first-page":"11950","DOI":"10.1128\/JVI.01672-13","article-title":"Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies","volume":"87","author":"Song","year":"2013","journal-title":"J. Virol."},{"key":"ref_341","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jfms.2003.12.011","article-title":"Modified vaccinia virus Ankara as a vaccine against feline coronavirus: Immunogenicity and efficacy","volume":"6","author":"Hebben","year":"2004","journal-title":"J. Feline Med. Surg."},{"key":"ref_342","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.vaccine.2004.05.015","article-title":"Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins","volume":"23","author":"Olszewska","year":"2004","journal-title":"Vaccine"},{"key":"ref_343","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S0264-410X(99)00257-1","article-title":"Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA","volume":"18","author":"Wyatt","year":"1999","journal-title":"Vaccine"},{"key":"ref_344","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.vaccine.2003.10.010","article-title":"Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology","volume":"22","author":"Wyatt","year":"2004","journal-title":"Vaccine"},{"key":"ref_345","doi-asserted-by":"crossref","first-page":"e2309","DOI":"10.1371\/journal.pntd.0002309","article-title":"A single immunization with MVA expressing GnGc glycoproteins promotes epitope-specific CD8+-T cell activation and protects immune-competent mice against a lethal RVFV infection","volume":"7","author":"Lorenzo","year":"2013","journal-title":"PLOS Negl. Trop. Dis."},{"key":"ref_346","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.antiviral.2014.05.020","article-title":"Efficacy assessment of an MVA vectored Rift Valley Fever vaccine in lambs","volume":"108","author":"Busquets","year":"2014","journal-title":"Antivir. Res."},{"key":"ref_347","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1016\/j.vaccine.2007.02.084","article-title":"Generation and evaluation of a recombinant modified vaccinia virus Ankara vaccine for rabies","volume":"25","author":"Weyer","year":"2007","journal-title":"Vaccine"},{"key":"ref_348","first-page":"125","article-title":"Different contribution of co-stimulatory molecules B7.1 and B7.2 to the immune response to recombinant modified vaccinia virus ankara vaccine expressing prM\/E proteins of Japanese encephalitis virus and two hepatitis B virus vaccines","volume":"51","author":"Nam","year":"2007","journal-title":"Acta Virol."},{"key":"ref_349","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0264-410X(98)00156-X","article-title":"Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes","volume":"17","author":"Nam","year":"1999","journal-title":"Vaccine"},{"key":"ref_350","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1348-0421.2002.tb02672.x","article-title":"Immunogenicity of a recombinant MVA and a DNA vaccine for Japanese encephalitis virus in swine","volume":"46","author":"Nam","year":"2002","journal-title":"Microbiol. Immunol."},{"key":"ref_351","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.1186\/1743-422X-9-204","article-title":"Multiple linear epitopes (B-cell, CTL and Th) of JEV expressed in recombinant MVA as multiple epitope vaccine induces a protective immune response","volume":"9","author":"Wang","year":"2012","journal-title":"Virol. J."},{"key":"ref_352","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1016\/S0264-410X(00)00531-4","article-title":"Vaccination with recombinant modified vaccinia virus Ankara protects against measles virus infection in the mouse and cotton rat model","volume":"19","author":"Weidinger","year":"2001","journal-title":"Vaccine"},{"key":"ref_353","doi-asserted-by":"crossref","first-page":"3700","DOI":"10.1016\/S0264-410X(01)00075-5","article-title":"Safety of modified vaccinia virus Ankara (MVA) in immune-suppressed macaques","volume":"19","author":"Stittelaar","year":"2001","journal-title":"Vaccine"},{"key":"ref_354","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1128\/JVI.78.8.3965-3976.2004","article-title":"Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus","volume":"78","author":"Wang","year":"2004","journal-title":"J. Virol."},{"key":"ref_355","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.jcv.2005.09.018","article-title":"Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection","volume":"35","author":"Wang","year":"2006","journal-title":"J. Clin. Virol."},{"key":"ref_356","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.vaccine.2006.09.067","article-title":"Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1","volume":"25","author":"Wang","year":"2007","journal-title":"Vaccine"},{"key":"ref_357","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1128\/JVI.00883-10","article-title":"Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques","volume":"85","author":"Abel","year":"2011","journal-title":"J. Virol."},{"key":"ref_358","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00430-008-0074-5","article-title":"Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques","volume":"197","author":"Yue","year":"2008","journal-title":"Med. Microbiol. Immunol."},{"key":"ref_359","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.virol.2008.04.034","article-title":"A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector","volume":"377","author":"Wang","year":"2008","journal-title":"Virology"},{"key":"ref_360","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.virol.2010.04.015","article-title":"Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses","volume":"403","author":"Manuel","year":"2010","journal-title":"Virology"},{"key":"ref_361","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1128\/JVI.01669-12","article-title":"A vaccine based on the rhesus cytomegalovirus UL128 complex induces broadly neutralizing antibodies in rhesus macaques","volume":"87","author":"Wussow","year":"2013","journal-title":"J. Virol."},{"key":"ref_362","doi-asserted-by":"crossref","first-page":"e1004524","DOI":"10.1371\/journal.ppat.1004524","article-title":"Human Cytomegalovirus Vaccine Based on the Envelope gH\/gL Pentamer Complex","volume":"10","author":"Wussow","year":"2014","journal-title":"PLOS Pathog."},{"key":"ref_363","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1089\/vim.2011.0018","article-title":"Recombinant MVA expressing secreted glycoprotein D of BoHV-1 induces systemic and mucosal immunity in animal models","volume":"24","author":"Ferrer","year":"2011","journal-title":"Viral Immunol."},{"key":"ref_364","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0264-410X(99)00413-2","article-title":"Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA\/DNA vaccination scheme","volume":"18","author":"Huemer","year":"2000","journal-title":"Vaccine"},{"key":"ref_365","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1089\/vim.2006.19.250","article-title":"Evaluation of a needle-free delivery platform for prime-boost immunization with DNA and modified vaccinia virus ankara vectors expressing herpes simplex virus 2 glycoprotein D","volume":"19","author":"Meseda","year":"2006","journal-title":"Viral Immunol."},{"key":"ref_366","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0264-410X(96)00072-2","article-title":"Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model","volume":"14","author":"Wyatt","year":"1996","journal-title":"Vaccine"},{"key":"ref_367","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1086\/314769","article-title":"Comparison of the immunogenicity and efficacy of a replication-defective vaccinia virus expressing antigens of human parainfluenza virus type 3 (HPIV3) with those of a live attenuated HPIV3 vaccine candidate in rhesus monkeys passively immunized with PIV3 antibodies","volume":"179","author":"Durbin","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_368","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/S0264-410X(98)00010-3","article-title":"The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus type 3 recombinants in rhesus monkeys","volume":"16","author":"Durbin","year":"1998","journal-title":"Vaccine"},{"key":"ref_369","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.vaccine.2012.12.042","article-title":"Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery","volume":"31","author":"Meyer","year":"2013","journal-title":"Vaccine"},{"key":"ref_370","doi-asserted-by":"crossref","first-page":"e87340","DOI":"10.1371\/journal.pone.0087340","article-title":"The candidate TB vaccine, MVA85A, induces highly durable Th1 responses","volume":"9","author":"Tameris","year":"2014","journal-title":"PLOS ONE"},{"key":"ref_371","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","article-title":"Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: A randomised, placebo-controlled phase 2b trial","volume":"381","author":"Tameris","year":"2013","journal-title":"Lancet"},{"key":"ref_372","doi-asserted-by":"crossref","first-page":"4625","DOI":"10.1016\/j.vaccine.2014.06.075","article-title":"Vaccine strategies against Babesia bovis based on prime-boost immunizations in mice with modified vaccinia Ankara vector and recombinant proteins","volume":"32","author":"Zanetti","year":"2014","journal-title":"Vaccine"},{"key":"ref_373","doi-asserted-by":"crossref","first-page":"5891","DOI":"10.1016\/j.vaccine.2010.06.054","article-title":"Efficacy and safety of a modified vaccinia Ankara (MVA) vectored plague vaccine in mice","volume":"28","author":"Brewoo","year":"2010","journal-title":"Vaccine"},{"key":"ref_374","doi-asserted-by":"crossref","first-page":"e57726","DOI":"10.1371\/journal.pone.0057726","article-title":"Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults","volume":"8","author":"Ogwang","year":"2013","journal-title":"PLOS ONE"},{"key":"ref_375","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing CS & ME-TRAP Against Controlled Human Malaria Infection in Malaria Naive Individuals","volume":"211","author":"Hodgson","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_376","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PLOS ONE"},{"key":"ref_377","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1038\/mt.2012.223","article-title":"ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: Assessment of efficacy against mosquito bite challenge in humans","volume":"20","author":"Sheehy","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_378","doi-asserted-by":"crossref","first-page":"e107903","DOI":"10.1371\/journal.pone.0107903","article-title":"Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure","volume":"9","author":"Biswas","year":"2014","journal-title":"PLOS ONE"},{"key":"ref_379","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/imm.12226","article-title":"Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection","volume":"141","author":"Elias","year":"2014","journal-title":"Immunology"},{"key":"ref_380","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/mt.2014.157","article-title":"Combining Viral Vectored and Protein-in-adjuvant Vaccines Against the Blood-stage Malaria Antigen AMA1: Report on a Phase 1a Clinical Trial","volume":"22","author":"Hodgson","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_381","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","volume":"19","author":"Sheehy","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_382","doi-asserted-by":"crossref","first-page":"e12557","DOI":"10.1371\/journal.pone.0012557","article-title":"MIG and the regulatory cytokines IL-10 and TGF-beta1 correlate with malaria vaccine immunogenicity and efficacy","volume":"5","author":"Dunachie","year":"2010","journal-title":"PLOS ONE"},{"key":"ref_383","doi-asserted-by":"crossref","first-page":"7514","DOI":"10.1016\/j.vaccine.2011.03.083","article-title":"A human Phase I\/IIa malaria challenge trial of a polyprotein malaria vaccine","volume":"29","author":"Porter","year":"2011","journal-title":"Vaccine"},{"key":"ref_384","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.micinf.2005.10.004","article-title":"MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis","volume":"8","author":"Kochan","year":"2006","journal-title":"Microbes Infect."},{"key":"ref_385","doi-asserted-by":"crossref","first-page":"e38859","DOI":"10.1371\/journal.pone.0038859","article-title":"High quality long-term CD4+ and CD8+ effector memory populations stimulated by DNA-LACK\/MVA-LACK regimen in Leishmania major BALB\/c model of infection","volume":"7","author":"Gomez","year":"2012","journal-title":"PLOS ONE"},{"key":"ref_386","doi-asserted-by":"crossref","first-page":"6695","DOI":"10.1016\/j.vaccine.2009.08.091","article-title":"Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection","volume":"27","author":"Ramos","year":"2009","journal-title":"Vaccine"},{"key":"ref_387","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1128\/IAI.01490-06","article-title":"Heterologous priming-boosting with DNA and modified vaccinia virus Ankara expressing tryparedoxin peroxidase promotes long-term memory against Leishmania major in susceptible BALB\/c Mice","volume":"75","author":"Stober","year":"2007","journal-title":"Infect. Immun."},{"key":"ref_388","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.vaccine.2008.11.094","article-title":"A prime\/boost DNA\/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis","volume":"27","author":"Carson","year":"2009","journal-title":"Vaccine"},{"key":"ref_389","doi-asserted-by":"crossref","first-page":"e1204","DOI":"10.1371\/journal.pntd.0001204","article-title":"TLR1\/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia)","volume":"5","author":"Jayakumar","year":"2011","journal-title":"PLOS Negl. Trop. Dis."},{"key":"ref_390","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1017\/S0031182003004761","article-title":"MVA ROP2 vaccinia virus recombinant as a vaccine candidate for toxoplasmosis","volume":"128","author":"Rosales","year":"2004","journal-title":"Parasitology"},{"key":"ref_391","doi-asserted-by":"crossref","first-page":"e59434","DOI":"10.1371\/journal.pone.0059434","article-title":"TcVac3 induced control of Trypanosoma cruzi infection and chronic myocarditis in mice","volume":"8","author":"Gupta","year":"2013","journal-title":"PLOS ONE"},{"key":"ref_392","unstructured":"Paoletti, E., Taylor, J., Tartaglia, J., and Ross, L. (1998). Marek\u2019s disease virus recombinant poxvirus vaccine. (5,759,552), U.S. Patent."},{"key":"ref_393","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1439-0450.1966.tb00871.x","article-title":"Attenuation of virulent fowl pox virus in tissue culture and characteristics of the attenuated virus","volume":"13","author":"Mayr","year":"1966","journal-title":"Zentralbl. Veterinarmed. B"},{"key":"ref_394","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1099\/vir.0.19568-0","article-title":"Comparison of the genome sequence of FP9, an attenuated, tissue culture-adapted European strain of Fowlpox virus, with those of virulent American and European viruses","volume":"85","author":"Laidlaw","year":"2004","journal-title":"J. Gen. Virol."},{"key":"ref_395","unstructured":"Paoletti, E., Perkus, M.E., Taylor, J., Tartaglia, J., Norton, E.K., Riviere, M., de Taisne, C., Limbach, K.J., Johnson, G.P., and Pincus, S.E. (1998). Alvac canarypox virus recombinants comprising heterlogous inserts. (5,756,1036), U.S. Patent."},{"key":"ref_396","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1097\/00126334-200502010-00002","article-title":"Attenuated poxvirus-based simian immunodeficiency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV","volume":"38","author":"Abel","year":"2005","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_397","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1128\/JVI.76.1.292-302.2002","article-title":"ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A * 01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency","volume":"76","author":"Pal","year":"2002","journal-title":"J. Virol."},{"key":"ref_398","doi-asserted-by":"crossref","first-page":"3732","DOI":"10.1128\/JVI.80.8.3732-3742.2006","article-title":"Systemic immunization with an ALVAC-HIV-1\/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels","volume":"80","author":"Pal","year":"2006","journal-title":"J. Virol."},{"key":"ref_399","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1093\/infdis\/174.5.977","article-title":"Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys","volume":"174","author":"Andersson","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_400","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1006\/viro.1997.8560","article-title":"Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus","volume":"232","author":"Girard","year":"1997","journal-title":"Virology"},{"key":"ref_401","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1586\/14760584.3.4.S99","article-title":"ALVAC-HIV vaccines: Clinical trial experience focusing on progress in vaccine development","volume":"3","author":"Marovich","year":"2004","journal-title":"Expert Rev. Vaccines"},{"key":"ref_402","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.vaccine.2003.08.023","article-title":"Safety profile of recombinant canarypox HIV vaccines","volume":"22","author":"Rossini","year":"2004","journal-title":"Vaccine"},{"key":"ref_403","first-page":"165","article-title":"The safety and use of canarypox vectored vaccines","volume":"84","author":"Plotkin","year":"1995","journal-title":"Dev. Biol. Stand."},{"key":"ref_404","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"Pitisuttithum","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_405","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1637\/7628-042806R.1","article-title":"Efficacy of an inactivated and a fowlpox-vectored vaccine in Muscovy ducks against an Asian H5N1 highly pathogenic avian influenza viral challenge","volume":"51","author":"Steensels","year":"2007","journal-title":"Avian Dis."},{"key":"ref_406","first-page":"1340","article-title":"Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats","volume":"12","author":"Karaca","year":"2005","journal-title":"Clin. Diagn. Lab. Immunol."},{"key":"ref_407","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1128\/CVI.00487-09","article-title":"Characterization of host responses against a recombinant fowlpox virus-vectored vaccine expressing the hemagglutinin antigen of an avian influenza virus","volume":"17","author":"Hghihghi","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_408","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.vaccine.2009.02.006","article-title":"Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs","volume":"27","author":"Kyriakis","year":"2009","journal-title":"Vaccine"},{"key":"ref_409","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2307\/1592386","article-title":"Efficacy of a recombinant fowl pox-based Newcastle disease virus vaccine candidate against velogenic and respiratory challenge","volume":"40","author":"Taylor","year":"1996","journal-title":"Avian Dis."},{"key":"ref_410","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.4049\/jimmunol.169.9.4778","article-title":"Containment of simian immunodeficiency virus infection in vaccinated macaques: Correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses","volume":"169","author":"Hel","year":"2002","journal-title":"J. Immunol."},{"key":"ref_411","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1006\/viro.1993.1442","article-title":"Induction of cytotoxic T lymphocytes by recombinant canarypox (ALVAC) and attenuated vaccinia (NYVAC) viruses expressing the HIV-1 envelope glycoprotein","volume":"195","author":"Cox","year":"1993","journal-title":"Virology"},{"key":"ref_412","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1089\/aid.1995.11.373","article-title":"A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN\/LAI). The AGIS Group, and l\u2019Agence Nationale de Recherche sur le SIDA","volume":"11","author":"Pialoux","year":"1995","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_413","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/infdis\/174.4.734","article-title":"Memory cytotoxic T lymphocyte responses in human immunodeficiency virus type 1 (HIV-1)-negative volunteers immunized with a recombinant canarypox expressing gp 160 of HIV-1 and boosted with a recombinant gp160","volume":"174","author":"Fleury","year":"1996","journal-title":"J. Infect. Dis."},{"key":"ref_414","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1093\/infdis\/171.6.1623","article-title":"Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene","volume":"171","author":"Egan","year":"1995","journal-title":"J. Infect. Dis."},{"key":"ref_415","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1086\/515288","article-title":"Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group","volume":"177","author":"Weinhold","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_416","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1073\/pnas.94.4.1396","article-title":"Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers","volume":"94","author":"Ferrari","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_417","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1097\/00002030-199818000-00009","article-title":"Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group","volume":"12","author":"Belshe","year":"1998","journal-title":"AIDS"},{"key":"ref_418","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1089\/088922299310935","article-title":"Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm\/gag\/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L\u2019Agence Nationale de Recherches sur Le Sida","volume":"15","author":"Excler","year":"1999","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_419","doi-asserted-by":"crossref","unstructured":"AIDS Vaccine Evaluation Group 022 Protocol Team (2001). Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120: A phase 2 study in higher- and lower-risk volunteers. J. Infect. Dis., 183, 563\u2013570.","DOI":"10.1086\/318523"},{"key":"ref_420","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1086\/319863","article-title":"Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers","volume":"183","author":"Belshe","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_421","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00042560-200203010-00005","article-title":"Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A","volume":"29","author":"Gupta","year":"2002","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_422","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1086\/368020","article-title":"Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: Results of the HIV Network for Prevention Trials 007 Vaccine Study","volume":"187","author":"Cao","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_423","doi-asserted-by":"crossref","first-page":"e24254","DOI":"10.1371\/journal.pone.0024254","article-title":"A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells","volume":"6","author":"Eller","year":"2011","journal-title":"PLOS ONE"},{"key":"ref_424","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1086\/498163","article-title":"Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women","volume":"192","author":"Johnson","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_425","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1086\/314895","article-title":"A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers","volume":"180","author":"Evans","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_426","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1086\/422258","article-title":"Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults","volume":"190","author":"Nitayaphan","year":"2004","journal-title":"J. Infect. Dis."},{"key":"ref_427","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1016\/j.vaccine.2004.10.028","article-title":"Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I\/II ALVAC-HIV\/AIDSVAX B\/E prime-boost HIV-1 vaccine trial in Thailand","volume":"23","author":"Karnasuta","year":"2005","journal-title":"Vaccine"},{"key":"ref_428","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/QAI.0b013e3181354bd7","article-title":"A phase 1\/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023\/LAI-DID) or bivalent gp120 (CM235\/SF2) boost","volume":"46","author":"Thongcharoen","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_429","doi-asserted-by":"crossref","first-page":"e27837","DOI":"10.1371\/journal.pone.0027837","article-title":"Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B\/E vaccination in an efficacy trial in Thailand","volume":"6","author":"Pitisuttithum","year":"2011","journal-title":"PLOS ONE"},{"key":"ref_430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0b013e31827f1c2d","article-title":"Feasibility and safety of ALVAC-HIV vCP1521 vaccine in HIV-exposed infants in Uganda: Results from the first HIV vaccine trial in infants in Africa","volume":"63","author":"Kintu","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_431","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/01.qai.0000435600.65845.31","article-title":"Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): The first pediatric HIV vaccine trial in Africa","volume":"65","author":"Kaleebu","year":"2014","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_432","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1146\/annurev-med-052912-123749","article-title":"Lessons from the RV144 Thai Phase III HIV-1 Vaccine Trial and the Search for Correlates of Protection","volume":"66","author":"Kim","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_433","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/339003","article-title":"Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults","volume":"185","author":"Bernstein","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_434","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1086\/314951","article-title":"A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne)","volume":"180","author":"Adler","year":"1999","journal-title":"J. Infect. Dis."},{"key":"ref_435","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1086\/319680","article-title":"A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects","volume":"183","author":"Berencsi","year":"2001","journal-title":"J. Infect. Dis."},{"key":"ref_436","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/0264-410X(94)00028-L","article-title":"Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species","volume":"13","author":"Taylor","year":"1995","journal-title":"Vaccine"},{"key":"ref_437","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0264-410X(95)00171-V","article-title":"Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: An alternative poxvirus vector system","volume":"14","author":"Fries","year":"1996","journal-title":"Vaccine"},{"key":"ref_438","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/0140-6736(92)92027-D","article-title":"Immunisation with canarypox virus expressing rabies glycoprotein","volume":"339","author":"Cadoz","year":"1992","journal-title":"Lancet"},{"key":"ref_439","doi-asserted-by":"crossref","first-page":"833","DOI":"10.2460\/ajvr.1997.58.08.833","article-title":"Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins","volume":"58","author":"Pardo","year":"1997","journal-title":"Am. J. Vet. Res."},{"key":"ref_440","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1128\/jvi.71.2.1506-1513.1997","article-title":"Canine distemper virus (CDV) infection of ferrets as a model for testing Morbillivirus vaccine strategies: NYVAC- and ALVAC-based CDV recombinants protect against symptomatic infection","volume":"71","author":"Stephensen","year":"1997","journal-title":"J. Virol."},{"key":"ref_441","doi-asserted-by":"crossref","first-page":"6358","DOI":"10.1128\/JVI.74.14.6358-6367.2000","article-title":"Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines","volume":"74","author":"Welter","year":"2000","journal-title":"J. Virol."},{"key":"ref_442","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S0264-410X(98)00211-4","article-title":"Mucosal vaccination with recombinant poxvirus vaccines protects ferrets against symptomatic CDV infection","volume":"17","author":"Welter","year":"1999","journal-title":"Vaccine"},{"key":"ref_443","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2460\/ajvr.2004.65.1459","article-title":"Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses","volume":"65","author":"Siger","year":"2004","journal-title":"Am. J. Vet. Res."},{"key":"ref_444","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.vetimm.2008.02.002","article-title":"A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse","volume":"123","author":"Minke","year":"2008","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_445","doi-asserted-by":"crossref","first-page":"4608","DOI":"10.1016\/j.vaccine.2011.04.058","article-title":"Protection provided by a recombinant ALVAC((R))-WNV vaccine expressing the prM\/E genes of a lineage 1 strain of WNV against a virulent challenge with a lineage 2 strain","volume":"29","author":"Minke","year":"2011","journal-title":"Vaccine"},{"key":"ref_446","first-page":"221","article-title":"Recombinant canarypoxvirus vaccine carrying the prM\/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge","volume":"18","author":"Minke","year":"2004","journal-title":"Arch. Virol. Suppl."},{"key":"ref_447","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1016\/j.vaccine.2005.02.020","article-title":"Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge","volume":"23","author":"Karaca","year":"2005","journal-title":"Vaccine"},{"key":"ref_448","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1128\/jvi.67.4.2370-2375.1993","article-title":"Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL","volume":"67","author":"Tartaglia","year":"1993","journal-title":"J. Virol."},{"key":"ref_449","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1136\/vr.153.5.141","article-title":"Efficacy of a canarypox virus-vectored vaccine against feline leukaemia","volume":"153","author":"Poulet","year":"2003","journal-title":"Vet. Rec."},{"key":"ref_450","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.vaccine.2005.09.010","article-title":"Reassessment of feline leukaemia virus (FeLV) vaccines with novel sensitive molecular assays","volume":"24","author":"Tandon","year":"2006","journal-title":"Vaccine"},{"key":"ref_451","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/00002030-199801000-00002","article-title":"Efficacy evaluation of prime-boost protocol: Canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats","volume":"12","author":"Tellier","year":"1998","journal-title":"AIDS"},{"key":"ref_452","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1051\/vetres:2004019","article-title":"Equine viral vaccines: The past, present and future","volume":"35","author":"Minke","year":"2004","journal-title":"Vet. Res."},{"key":"ref_453","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.vetimm.2009.11.007","article-title":"Onset and duration of immunity to equine influenza virus resulting from canarypox-vectored (ALVAC) vaccination","volume":"135","author":"Soboll","year":"2010","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_454","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.vetimm.2006.02.007","article-title":"Antibody and IFN-gamma responses induced by a recombinant canarypox vaccine and challenge infection with equine influenza virus","volume":"112","author":"Paillot","year":"2006","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_455","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.vaccine.2005.10.019","article-title":"Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection","volume":"24","author":"Paillot","year":"2006","journal-title":"Vaccine"},{"key":"ref_456","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0264-410X(00)00191-2","article-title":"Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus\u2014Poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans","volume":"19","author":"Smucny","year":"2000","journal-title":"Vaccine"},{"key":"ref_457","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0264-410X(97)00265-X","article-title":"Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates","volume":"16","author":"Konishi","year":"1998","journal-title":"Vaccine"},{"key":"ref_458","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/aid.1995.11.307","article-title":"Highly attenuated HTLV type Ienv poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits","volume":"11","author":"Franchini","year":"1995","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_459","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1016\/j.vaccine.2009.05.044","article-title":"Protective immunization of horses with a recombinant canarypox virus vectored vaccine co-expressing genes encoding the outer capsid proteins of African horse sickness virus","volume":"27","author":"Guthrie","year":"2009","journal-title":"Vaccine"},{"key":"ref_460","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.vetimm.2012.06.009","article-title":"An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses","volume":"149","author":"Crafford","year":"2012","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_461","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S0264-410X(96)00102-8","article-title":"A recombinant canarypox virus protects rabbits against a lethal rabbit hemorrhagic disease virus (RHDV) challenge","volume":"15","author":"Fischer","year":"1997","journal-title":"Vaccine"},{"key":"ref_462","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0022-1759(98)00054-4","article-title":"Hepatitis C virus-specific CTL responses in PBMC from chimpanzees with chronic hepatitis C: Determination of CTL and CTL precursor frequencies using a recombinant canarypox virus (ALVAC)","volume":"214","author":"Cohard","year":"1998","journal-title":"J. Immunol. Methods"},{"key":"ref_463","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.vaccine.2006.08.025","article-title":"Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep","volume":"25","author":"Boone","year":"2007","journal-title":"Vaccine"},{"key":"ref_464","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1016\/j.vaccine.2010.05.028","article-title":"Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine","volume":"28","author":"Stittelaar","year":"2010","journal-title":"Vaccine"},{"key":"ref_465","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2567.2004.01903.x","article-title":"Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin","volume":"112","author":"Vordermeier","year":"2004","journal-title":"Immunology"},{"key":"ref_466","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.4049\/jimmunol.172.5.3094","article-title":"Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus","volume":"172","author":"Anderson","year":"2004","journal-title":"J. Immunol."},{"key":"ref_467","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1073\/pnas.0307158101","article-title":"A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses","volume":"101","author":"Prieur","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_468","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1371\/journal.pctr.0010029","article-title":"A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya","volume":"1","author":"Bejon","year":"2006","journal-title":"PLOS Clin. Trials"},{"key":"ref_469","doi-asserted-by":"crossref","first-page":"4709","DOI":"10.1016\/j.vaccine.2006.03.029","article-title":"Immunogenicity of the candidate malaria vaccines FP9 and modified vaccinia virus Ankara encoding the pre-erythrocytic antigen ME-TRAP in 1\u20136 year old children in a malaria endemic area","volume":"24","author":"Bejon","year":"2006","journal-title":"Vaccine"},{"key":"ref_470","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1128\/IAI.74.5.2706-2716.2006","article-title":"Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein","volume":"74","author":"Walther","year":"2006","journal-title":"Infect. Immun."},{"key":"ref_471","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1086\/501459","article-title":"Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya","volume":"42","author":"Bejon","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_472","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1073\/pnas.0406381102","article-title":"Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara","volume":"102","author":"Webster","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_473","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1016\/j.vaccine.2005.10.058","article-title":"Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers","volume":"24","author":"Webster","year":"2006","journal-title":"Vaccine"},{"key":"ref_474","doi-asserted-by":"crossref","first-page":"6526","DOI":"10.1016\/j.vaccine.2006.06.022","article-title":"Safety and immunogenicity of the malaria candidate vaccines FP9 CS and MVA CS in adult Gambian men","volume":"24","author":"Imoukhuede","year":"2006","journal-title":"Vaccine"},{"key":"ref_475","doi-asserted-by":"crossref","first-page":"e135","DOI":"10.1186\/1475-2875-6-135","article-title":"Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime\/poxvirus boost immunization","volume":"6","author":"Jiang","year":"2007","journal-title":"Malar. J."},{"key":"ref_476","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1128\/IAI.69.9.5565-5572.2001","article-title":"Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques","volume":"69","author":"Rogers","year":"2001","journal-title":"Infect. Immun."},{"key":"ref_477","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1016\/j.vaccine.2013.05.091","article-title":"Utilizing poxviral vectored vaccines for antibody induction-progress and prospects","volume":"31","author":"Draper","year":"2013","journal-title":"Vaccine"},{"key":"ref_478","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4161\/hv.6.1.10116","article-title":"Prime-boost vectored malaria vaccines: Progress and prospects","volume":"6","author":"Hill","year":"2010","journal-title":"Hum. Vaccine"},{"key":"ref_479","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/18715206113136660376","article-title":"Poxvirus-based vaccines for cancer immunotherapy: New insights from combined cytokines\/co-stimulatory molecules delivery and \u201cuncommon\u201d strains","volume":"14","author":"Izzi","year":"2014","journal-title":"Anti -Cancer Agents Med. Chem."},{"key":"ref_480","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/COH.0b013e32833d1e87","article-title":"Poxvirus vector-based HIV vaccines","volume":"5","author":"Pantaleo","year":"2010","journal-title":"Curr. Opin. HIV AIDS"},{"key":"ref_481","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.4161\/hv.28974","article-title":"Enhancing poxvirus vectors vaccine immunogenicity","volume":"10","author":"Esteban","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_482","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1089\/aid.1992.8.1445","article-title":"Highly attenuated poxvirus vectors","volume":"8","author":"Tartaglia","year":"1992","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_483","first-page":"125","article-title":"Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC","volume":"82","author":"Tartaglia","year":"1994","journal-title":"Dev. Biol. Stand."},{"key":"ref_484","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0042-6822(92)90752-B","article-title":"NYVAC: A highly attenuated strain of vaccinia virus","volume":"188","author":"Tartaglia","year":"1992","journal-title":"Virology"},{"key":"ref_485","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/j.vaccine.2006.09.090","article-title":"Head-to-head comparison on the immunogenicity of two HIV\/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B","volume":"25","author":"Gomez","year":"2007","journal-title":"Vaccine"},{"key":"ref_486","doi-asserted-by":"crossref","first-page":"5881","DOI":"10.1128\/JVI.02345-08","article-title":"Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodeficiency virus type 1 clade C immunogens","volume":"83","author":"Mooij","year":"2009","journal-title":"J. Virol."},{"key":"ref_487","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1128\/JVI.02216-07","article-title":"Differential CD4+ versus CD8+ T-cell responses elicited by different poxvirus-based human immunodeficiency virus type 1 vaccine candidates provide comparable efficacies in primates","volume":"82","author":"Mooij","year":"2008","journal-title":"J. Virol."},{"key":"ref_488","doi-asserted-by":"crossref","first-page":"7131","DOI":"10.1073\/pnas.1103869108","article-title":"Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates","volume":"108","author":"Flynn","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_489","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0034-5288(97)90205-8","article-title":"Successful pseudorabies vaccination in maternally immune piglets using recombinant vaccinia virus vaccines","volume":"62","author":"Brockmeier","year":"1997","journal-title":"Res. Vet. Sci."},{"key":"ref_490","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0378-1135(97)00161-2","article-title":"Vaccination with recombinant vaccinia virus vaccines expressing glycoprotein genes of pseudorabies virus in the presence of maternal immunity","volume":"58","author":"Brockmeier","year":"1997","journal-title":"Vet. Microbiol."},{"key":"ref_491","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/0264-410X(95)00226-Q","article-title":"Comparison of the efficacy of replication-defective adenovirus and Nyvac poxvirus as vaccine vectors in mice","volume":"14","author":"Gonin","year":"1996","journal-title":"Vaccine"},{"key":"ref_492","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0378-1135(93)90074-H","article-title":"Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses","volume":"38","author":"Brockmeier","year":"1993","journal-title":"Vet. Microbiol."},{"key":"ref_493","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF01310565","article-title":"Evaluation of a recombinant vaccinia virus containing pseudorabies (PR) virus glycoprotein genes gp50, gII, and gIII as a PR vaccine for pigs","volume":"134","author":"Mengeling","year":"1994","journal-title":"Arch. Virol."},{"key":"ref_494","first-page":"315","article-title":"Comparison of the protective response induced by NYVAC vaccinia recombinants expressing either gp50 or gII and gp50 of pseudorabies virus","volume":"60","author":"Brockmeier","year":"1996","journal-title":"Can. J. Vet. Res."},{"key":"ref_495","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.4049\/jimmunol.167.12.7180","article-title":"Potentiation of simian immunodeficiency virus (SIV)-specific CD4(+) and CD8(+) T cell responses by a DNA-SIV and NYVAC-SIV prime\/boost regimen","volume":"167","author":"Hel","year":"2001","journal-title":"J. Immunol."},{"key":"ref_496","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1128\/JVI.72.5.4170-4182.1998","article-title":"Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): Dependence on route of challenge exposure","volume":"72","author":"Benson","year":"1998","journal-title":"J. Virol."},{"key":"ref_497","doi-asserted-by":"crossref","first-page":"11659","DOI":"10.1128\/JVI.76.22.11659-11676.2002","article-title":"Both mucosal and systemic routes of immunization with the live, attenuated NYVAC\/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques","volume":"76","author":"Stevceva","year":"2002","journal-title":"J. Virol."},{"key":"ref_498","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1128\/JVI.02469-14","article-title":"Virological and immunological characterization of novel NYVAC-based HIV\/AIDS vaccine candidates expressing clade C trimeric soluble gp140(ZM96) and Gag(ZM96)-Pol-Nef(CN54) as VLPs","volume":"89","author":"Perdiguero","year":"2015","journal-title":"J. Virol."},{"key":"ref_499","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20071331","article-title":"An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses","volume":"205","author":"Harari","year":"2008","journal-title":"J. Exp. Med."},{"key":"ref_500","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1016\/j.vaccine.2008.03.083","article-title":"EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium","volume":"26","author":"Bart","year":"2008","journal-title":"Vaccine"},{"key":"ref_501","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1016\/j.vaccine.2008.02.072","article-title":"EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone","volume":"26","author":"McCormack","year":"2008","journal-title":"Vaccine"},{"key":"ref_502","unstructured":"Levy, Y., Ellefsen, K., St\u00f6ehr, W., Bart, P.A., Leli\u00e8vere, J.D., Launay, O., Wolf, H., Weber, J., Ch\u00eane, G., and Pantaleo, G. Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens requires 3 DNA injection. Results of the randomized multicentre EV03\/ANRS Vac20 Phase I\/II Trial. Available online: http:\/\/www.immunologyresearch.ch\/ial-vic-abstract-ev03-croi_2010.pdf."},{"key":"ref_503","doi-asserted-by":"crossref","first-page":"9854","DOI":"10.1128\/JVI.00788-11","article-title":"DNA\/NYVAC vaccine regimen induces HIV-specific CD4 and CD8 T-cell responses in intestinal mucosa","volume":"85","author":"Perreau","year":"2011","journal-title":"J. Virol."},{"key":"ref_504","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/eji.201242696","article-title":"NYVAC immunization induces polyfunctional HIV-specific T-cell responses in chronically-infected, ART-treated HIV patients","volume":"42","author":"Harari","year":"2012","journal-title":"Eur. J. Immunol."},{"key":"ref_505","doi-asserted-by":"crossref","first-page":"4843","DOI":"10.1172\/JCI75894","article-title":"HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial","volume":"124","author":"Bart","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_506","doi-asserted-by":"crossref","first-page":"5939","DOI":"10.1128\/JVI.75.13.5939-5948.2001","article-title":"Immunogenicity and protective efficacy of recombinant human T-cell leukemia\/lymphoma virus type 1 NYVAC and naked DNA vaccine candidates in squirrel monkeys (Saimiri sciureus)","volume":"75","author":"Kazanji","year":"2001","journal-title":"J. Virol."},{"key":"ref_507","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/aid.1996.12.407","article-title":"Attenuated poxvirus vectors as carriers in vaccines against human T cell leukemia-lymphoma virus type I","volume":"12","author":"Franchini","year":"1996","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"ref_508","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/intimm\/9.5.731","article-title":"Recombinant vaccinia viruses for the characterization of Plasmodium falciparum-specific cytotoxic T lymphocytes: Recognition of processed antigen despite limited re-stimulation efficacy","volume":"9","author":"Aidoo","year":"1997","journal-title":"Int. Immunol."},{"key":"ref_509","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1086\/515331","article-title":"Phase I\/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria","volume":"177","author":"Ockenhouse","year":"1998","journal-title":"J. Infect. Dis."},{"key":"ref_510","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.vaccine.2008.03.044","article-title":"Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: Scarification vaccination","volume":"26","author":"Jentarra","year":"2008","journal-title":"Vaccine"},{"key":"ref_511","doi-asserted-by":"crossref","first-page":"e1638","DOI":"10.1371\/journal.pone.0001638","article-title":"Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA)","volume":"3","author":"Cottingham","year":"2008","journal-title":"PLOS ONE"},{"key":"ref_512","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1099\/vir.0.80646-0","article-title":"Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara","volume":"86","author":"Staib","year":"2005","journal-title":"J. Gen. Virol."},{"key":"ref_513","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1186\/1743-422X-10-34","article-title":"Interleukin-1beta receptor expressed by modified vaccinia virus Ankara interferes with interleukin-1beta activity produced in various virus-infected antigen-presenting cells","volume":"10","author":"Zimmerling","year":"2013","journal-title":"Virol. J."},{"key":"ref_514","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1099\/vir.0.81417-0","article-title":"Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy","volume":"87","author":"Clark","year":"2006","journal-title":"J. Gen. Virol."},{"key":"ref_515","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1128\/JVI.78.6.2770-2779.2004","article-title":"Induction of potent humoral and cell-mediated immune responses by attenuated vaccinia virus vectors with deleted serpin genes","volume":"78","author":"Legrand","year":"2004","journal-title":"J. Virol."},{"key":"ref_516","doi-asserted-by":"crossref","first-page":"e32220","DOI":"10.1371\/journal.pone.0032220","article-title":"Improving the MVA vaccine potential by deleting the viral gene coding for the IL-18 binding protein","volume":"7","author":"Falivene","year":"2012","journal-title":"PLOS ONE"},{"key":"ref_517","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1016\/j.vaccine.2011.02.023","article-title":"Deletion of the A35 gene from Modified Vaccinia Virus Ankara increases immunogenicity and isotype switching","volume":"29","author":"Rehm","year":"2011","journal-title":"Vaccine"},{"key":"ref_518","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1099\/vir.0.049700-0","article-title":"Deletion of immunomodulator C6 from vaccinia virus strain Western Reserve enhances virus immunogenicity and vaccine efficacy","volume":"94","author":"Sumner","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_519","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1128\/jvi.69.8.4633-4639.1995","article-title":"Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity","volume":"69","author":"Alcami","year":"1995","journal-title":"J. Virol."},{"key":"ref_520","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/0167-5699(95)80030-1","article-title":"Cytokine receptors encoded by poxviruses: A lesson in cytokine biology","volume":"16","author":"Alcami","year":"1995","journal-title":"Immunol Today"},{"key":"ref_521","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1099\/vir.0.054114-0","article-title":"Vaccinia virus protein N2 is a nuclear IRF3 inhibitor that promotes virulence","volume":"94","author":"Ferguson","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_522","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1099\/vir.0.2008\/004895-0","article-title":"Vaccinia virus protein C16 acts intracellularly to modulate the host response and promote virulence","volume":"89","author":"Fahy","year":"2008","journal-title":"J. Gen. Virol."},{"key":"ref_523","doi-asserted-by":"crossref","first-page":"6554","DOI":"10.1128\/JVI.79.10.6554-6559.2005","article-title":"Role of genes that modulate host immune responses in the immunogenicity and pathogenicity of vaccinia virus","volume":"79","author":"Jackson","year":"2005","journal-title":"J. Virol."},{"key":"ref_524","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1016\/j.vaccine.2008.06.011","article-title":"Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes","volume":"26","author":"Dai","year":"2008","journal-title":"Vaccine"},{"key":"ref_525","doi-asserted-by":"crossref","first-page":"5016","DOI":"10.1128\/JVI.02359-10","article-title":"Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice","volume":"85","author":"Dimier","year":"2011","journal-title":"J. Virol."},{"key":"ref_526","doi-asserted-by":"crossref","first-page":"9907","DOI":"10.1128\/JVI.00756-10","article-title":"Introduction of the six major genomic deletions of modified vaccinia virus Ankara (MVA) into the parental vaccinia virus is not sufficient to reproduce an MVA-like phenotype in cell culture and in mice","volume":"84","author":"Spath","year":"2010","journal-title":"J. Virol."},{"key":"ref_527","doi-asserted-by":"crossref","first-page":"e66894","DOI":"10.1371\/journal.pone.0066894","article-title":"Improving Adaptive and Memory Immune Responses of an HIV\/AIDS Vaccine Candidate MVA-B by Deletion of Vaccinia Virus Genes (C6L and K7R) Blocking Interferon Signaling Pathways","volume":"8","author":"Arnaez","year":"2013","journal-title":"PLOS ONE"},{"key":"ref_528","doi-asserted-by":"crossref","first-page":"e12395","DOI":"10.1371\/journal.pone.0012395","article-title":"Immunogenic profiling in mice of a HIV\/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletions","volume":"5","author":"Najera","year":"2010","journal-title":"PLOS ONE"},{"key":"ref_529","doi-asserted-by":"crossref","first-page":"e24244","DOI":"10.1371\/journal.pone.0024244","article-title":"A candidate HIV\/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responses","volume":"6","author":"Najera","year":"2011","journal-title":"PLOS ONE"},{"key":"ref_530","doi-asserted-by":"crossref","first-page":"5026","DOI":"10.1128\/JVI.06684-11","article-title":"Removal of vaccinia virus genes that block interferon type I and II pathways improves adaptive and memory responses of the HIV\/AIDS vaccine candidate NYVAC-C in mice","volume":"86","author":"Gomez","year":"2012","journal-title":"J. Virol."},{"key":"ref_531","doi-asserted-by":"crossref","first-page":"e74831","DOI":"10.1371\/journal.pone.0074831","article-title":"Deletion of the vaccinia virus gene A46R, encoding for an inhibitor of TLR signalling, is an effective approach to enhance the immunogenicity in mice of the HIV\/AIDS vaccine candidate NYVAC-C","volume":"8","author":"Perdiguero","year":"2013","journal-title":"PLOS ONE"},{"key":"ref_532","doi-asserted-by":"crossref","first-page":"e48524","DOI":"10.1371\/journal.pone.0048524","article-title":"Deletion of the viral anti-apoptotic gene F1L in the HIV\/AIDS vaccine candidate MVA-C enhances immune responses against HIV-1 antigens","volume":"7","author":"Perdiguero","year":"2012","journal-title":"PLOS ONE"},{"key":"ref_533","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1128\/JVI.00246-12","article-title":"Deletion of specific immune-modulatory genes from modified vaccinia virus Ankara-based HIV vaccines engenders improved immunogenicity in rhesus macaques","volume":"86","author":"Garber","year":"2012","journal-title":"J. Virol."},{"key":"ref_534","doi-asserted-by":"crossref","first-page":"e5445","DOI":"10.1371\/journal.pone.0005445","article-title":"Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies","volume":"4","author":"Garber","year":"2009","journal-title":"PLOS ONE"},{"key":"ref_535","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1128\/JVI.03061-14","article-title":"Interleukin 1- and type I interferon-dependent enhancement of the innate immune profile of a NYVAC-HIV-1 Env-Gag-Pol-Nef vaccine vector with dual deletion of type I and type II interferon-binding proteins","volume":"89","author":"Delaloye","year":"2015","journal-title":"J. Virol."},{"key":"ref_536","doi-asserted-by":"crossref","first-page":"e35485","DOI":"10.1371\/journal.pone.0035485","article-title":"Systems analysis of MVA-C induced immune response reveals its significance as a vaccine candidate against HIV\/AIDS of clade C","volume":"7","author":"Gomez","year":"2012","journal-title":"PLOS ONE"},{"key":"ref_537","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1128\/JVI.02723-13","article-title":"Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens","volume":"88","author":"Gomez","year":"2014","journal-title":"J. Virol."},{"key":"ref_538","doi-asserted-by":"crossref","first-page":"9684","DOI":"10.1016\/j.vaccine.2011.09.135","article-title":"Attenuated NYCBH vaccinia virus deleted for the E3L gene confers partial protection against lethal monkeypox virus disease in cynomolgus macaques","volume":"29","author":"Denzler","year":"2011","journal-title":"Vaccine"},{"key":"ref_539","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1016\/j.vaccine.2011.07.140","article-title":"The NYCBH vaccinia virus deleted for the innate immune evasion gene, E3L, protects rabbits against lethal challenge by rabbitpox virus","volume":"29","author":"Denzler","year":"2011","journal-title":"Vaccine"},{"key":"ref_540","doi-asserted-by":"crossref","first-page":"9691","DOI":"10.1016\/j.vaccine.2011.09.108","article-title":"The attenuated NYCBH vaccinia virus deleted for the immune evasion gene, E3L, completely protects mice against heterologous challenge with ectromelia virus","volume":"29","author":"Denzler","year":"2011","journal-title":"Vaccine"},{"key":"ref_541","first-page":"512","article-title":"Induction of potent immune responses by recombinant fowlpox virus with deleted ORF73 or ORF214","volume":"50","author":"Wang","year":"2010","journal-title":"Wei Sheng Wu Xue Bao"},{"key":"ref_542","doi-asserted-by":"crossref","first-page":"e25674","DOI":"10.1371\/journal.pone.0025674","article-title":"Improved NYVAC-based vaccine vectors","volume":"6","author":"Kibler","year":"2011","journal-title":"PLOS ONE"},{"key":"ref_543","doi-asserted-by":"crossref","first-page":"e16819","DOI":"10.1371\/journal.pone.0016819","article-title":"Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors","volume":"6","author":"Quakkelaar","year":"2011","journal-title":"PLOS ONE"},{"key":"ref_544","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1128\/JVI.75.3.1205-1210.2001","article-title":"Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox","volume":"75","author":"Jackson","year":"2001","journal-title":"J. Virol."},{"key":"ref_545","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.virol.2004.02.031","article-title":"Expression of rabbit IL-4 by recombinant myxoma viruses enhances virulence and overcomes genetic resistance to myxomatosis","volume":"324","author":"Kerr","year":"2004","journal-title":"Virology"},{"key":"ref_546","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.it.2005.04.001","article-title":"The \u201csupervirus\u201d? Lessons from IL-4-expressing poxviruses","volume":"26","author":"Stanford","year":"2005","journal-title":"Trends Immunol."},{"key":"ref_547","doi-asserted-by":"crossref","first-page":"e11406","DOI":"10.1371\/journal.pone.0011406","article-title":"Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens","volume":"5","author":"Najera","year":"2010","journal-title":"PLOS ONE"},{"key":"ref_548","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1006\/viro.2001.0945","article-title":"Induction of adult-like antibody, Th1, and CTL responses to measles hemagglutinin by early life murine immunization with an attenuated vaccinia-derived NYVAC(K1L) viral vector","volume":"285","author":"Kovarik","year":"2001","journal-title":"Virology"},{"key":"ref_549","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1086\/432915","article-title":"High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects","volume":"192","author":"Goepfert","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_550","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/QAI.0b013e318149297d","article-title":"Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120","volume":"46","author":"Cleghorn","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_551","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/01.qai.0000248356.48501.ff","article-title":"Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: Negative results fail to trigger a phase 3 correlates trial","volume":"44","author":"Russell","year":"2007","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_552","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1016\/j.vaccine.2008.05.018","article-title":"CD40L expressed from the canarypox vector, ALVAC, can boost immunogenicity of HIV-1 canarypox vaccine in mice and enhance the in vitro expansion of viral specific CD8+ T cell memory responses from HIV-1-infected and HIV-1-uninfected individuals","volume":"26","author":"Liu","year":"2008","journal-title":"Vaccine"},{"key":"ref_553","doi-asserted-by":"crossref","first-page":"6088","DOI":"10.1016\/j.vaccine.2009.05.016","article-title":"A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy","volume":"27","author":"Gandhi","year":"2009","journal-title":"Vaccine"},{"key":"ref_554","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/QAD.0b013e328344cea5","article-title":"A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune","volume":"25","author":"Angel","year":"2011","journal-title":"AIDS"},{"key":"ref_555","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1128\/CVI.00450-14","article-title":"Phase I\/II randomized trial of safety and immunogenicity of LIPO-5 alone, ALVAC-HIV (vCP1452) alone, and ALVAC-HIV (vCP1452) prime\/LIPO-5 boost in healthy, HIV-1-uninfected adult participants","volume":"21","author":"Frey","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_556","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/jvi.76.5.2206-2216.2002","article-title":"Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy","volume":"76","author":"Jin","year":"2002","journal-title":"J. Virol."},{"key":"ref_557","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1128\/iai.64.5.1666-1671.1996","article-title":"Attenuated vaccinia virus-circumsporozoite protein recombinants confer protection against rodent malaria","volume":"64","author":"Lanar","year":"1996","journal-title":"Infect. Immun."},{"key":"ref_558","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.vaccine.2007.11.036","article-title":"Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines","volume":"26","author":"Wyatt","year":"2008","journal-title":"Vaccine"},{"key":"ref_559","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1128\/jvi.54.1.30-37.1985","article-title":"In vitro mutagenesis of the promoter region for a vaccinia virus gene: Evidence for tandem early and late regulatory signals","volume":"54","author":"Cochran","year":"1985","journal-title":"J. Virol."},{"key":"ref_560","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1128\/jvi.64.5.2448-2451.1990","article-title":"Removal of cryptic poxvirus transcription termination signals from the human immunodeficiency virus type 1 envelope gene enhances expression and immunogenicity of a recombinant vaccinia virus","volume":"64","author":"Earl","year":"1990","journal-title":"J. Virol."},{"key":"ref_561","first-page":"2538","article-title":"Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes","volume":"7","author":"Fuerst","year":"1987","journal-title":"Mol. Cell. Biol."},{"key":"ref_562","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.2144\/97236st07","article-title":"Compact, synthetic, vaccinia virus early\/late promoter for protein expression","volume":"23","author":"Chakrabarti","year":"1997","journal-title":"BioTechniques"},{"key":"ref_563","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1002\/eji.200838815","article-title":"Correlates of protection efficacy induced by vaccinia virus-specific CD8+ T-cell epitopes in the murine intranasal challenge model","volume":"39","author":"Moutaftsi","year":"2009","journal-title":"Eur. J. Immunol."},{"key":"ref_564","doi-asserted-by":"crossref","first-page":"G21","DOI":"10.1016\/j.vaccine.2009.10.011","article-title":"Definition of epitopes and antigens recognized by vaccinia specific immune responses: Their conservation in variola virus sequences, and use as a model system to study complex pathogens","volume":"27","author":"Sette","year":"2009","journal-title":"Vaccine"},{"key":"ref_565","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20070489","article-title":"Cross-competition of CD8+ T cells shapes the immunodominance hierarchy during boost vaccination","volume":"204","author":"Kastenmuller","year":"2007","journal-title":"J. Exp. Med."},{"key":"ref_566","first-page":"674","article-title":"Deficiency of two red-cell flavin enzymes in a population in Sardinia: Was glutathione reductase deficiency specifically selected for by malaria?","volume":"57","author":"Anderson","year":"1995","journal-title":"Am. J. Hum. Genet."},{"key":"ref_567","doi-asserted-by":"crossref","first-page":"11513","DOI":"10.1073\/pnas.1006594107","article-title":"Simultaneous high-resolution analysis of vaccinia virus and host cell transcriptomes by deep RNA sequencing","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_568","doi-asserted-by":"crossref","first-page":"e40167","DOI":"10.1371\/journal.pone.0040167","article-title":"Expression and cellular immunogenicity of a transgenic antigen driven by endogenous poxviral early promoters at their authentic loci in MVA","volume":"7","author":"Orubu","year":"2012","journal-title":"PLOS ONE"},{"key":"ref_569","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1016\/j.vaccine.2013.05.071","article-title":"Immunogenicity and safety of the vaccinia virus LC16m8Delta vector expressing SIV Gag under a strong or moderate promoter in a recombinant BCG prime-recombinant vaccinia virus boost protocol","volume":"31","author":"Sato","year":"2013","journal-title":"Vaccine"},{"key":"ref_570","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.vaccine.2013.12.022","article-title":"Effects of different promoters on the virulence and immunogenicity of a HIV-1 Env-expressing recombinant vaccinia vaccine","volume":"32","author":"Isshiki","year":"2014","journal-title":"Vaccine"},{"key":"ref_571","doi-asserted-by":"crossref","first-page":"8743","DOI":"10.1128\/JVI.00604-10","article-title":"Immediate-early expression of a recombinant antigen by modified vaccinia virus ankara breaks the immunodominance of strong vector-specific B8R antigen in acute and memory CD8 T-cell responses","volume":"84","author":"Baur","year":"2010","journal-title":"J. Virol."},{"key":"ref_572","doi-asserted-by":"crossref","first-page":"e73511","DOI":"10.1371\/journal.pone.0073511","article-title":"A novel naturally occurring tandem promoter in modified vaccinia virus ankara drives very early gene expression and potent immune responses","volume":"8","author":"Wennier","year":"2013","journal-title":"PLOS ONE"},{"key":"ref_573","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1099\/vir.0.057299-0","article-title":"New vaccinia virus promoter as a potential candidate for future vaccines","volume":"94","author":"Gomez","year":"2013","journal-title":"J. Gen. Virol."},{"key":"ref_574","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nrc2545","article-title":"Targeted and armed oncolytic poxviruses: A novel multi-mechanistic therapeutic class for cancer","volume":"9","author":"Kirn","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_575","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S0039-6060(03)00294-0","article-title":"The role of poxviruses in tumor immunotherapy","volume":"134","author":"Kaufman","year":"2003","journal-title":"Surgery"},{"key":"ref_576","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djs033","article-title":"Therapeutic cancer vaccines: Current status and moving forward","volume":"104","author":"Schlom","year":"2012","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_577","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1440-0960.1963.tb01670.x","article-title":"Viral Treatment of Skin Cancers","volume":"7","author":"Noguchi","year":"1963","journal-title":"Aust. J. Dermatol."},{"key":"ref_578","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/00002371-199308000-00009","article-title":"Vaccinia virus MUC1 immunization of mice: Immune response and protection against the growth of murine tumors bearing the MUC1 antigen","volume":"14","author":"Acres","year":"1993","journal-title":"J. Immunother. Emphas. Tumor Immunol."},{"key":"ref_579","first-page":"1129","article-title":"Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors","volume":"1","author":"Mulryan","year":"2002","journal-title":"Mol. Cancer Ther."},{"key":"ref_580","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ijc.2910630215","article-title":"A recombinant vaccinia virus expressing human prostate-specific antigen (PSA): Safety and immunogenicity in a non-human primate","volume":"63","author":"Hodge","year":"1995","journal-title":"Int. J. Cancer J. Int. Cancer"},{"key":"ref_581","doi-asserted-by":"crossref","first-page":"97","DOI":"10.7774\/cevr.2013.2.2.97","article-title":"Viral vectors for vaccine applications","volume":"2","author":"Choi","year":"2013","journal-title":"Clin. Exp. Vaccine Res."},{"key":"ref_582","first-page":"4567","article-title":"Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules","volume":"58","author":"Zajac","year":"1998","journal-title":"Cancer Res."},{"key":"ref_583","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/mt.2009.275","article-title":"Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma","volume":"18","author":"Adamina","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_584","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/JTO.0b013e31817c6b4f","article-title":"A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III\/IV Non-small cell lung cancer","volume":"3","author":"Ramlau","year":"2008","journal-title":"J. Thorac. oncol."},{"key":"ref_585","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/mt.2011.228","article-title":"Treating tumors with a vaccinia virus expressing IFNbeta illustrates the complex relationships between oncolytic ability and immunogenicity","volume":"20","author":"Wang","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_586","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/sj.cgt.7700066","article-title":"Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma","volume":"6","author":"Mastrangelo","year":"1999","journal-title":"Cancer Gene Ther."},{"key":"ref_587","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/sj.cgt.7701110","article-title":"Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene","volume":"15","author":"Chalikonda","year":"2008","journal-title":"Cancer Gene Ther."},{"key":"ref_588","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1089\/10430349950018724","article-title":"Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy","volume":"10","author":"Puhlmann","year":"1999","journal-title":"Hum. Gene Ther."},{"key":"ref_589","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1186\/1756-9966-33-2","article-title":"A novel oncolytic viral therapy and imaging technique for gastric cancer using a genetically engineered vaccinia virus carrying the human sodium iodide symporter","volume":"33","author":"Jun","year":"2014","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_590","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00262-010-0850-0","article-title":"Local delivery of recombinant vaccinia virus encoding for neu counteracts growth of mammary tumors more efficiently than systemic delivery in neu transgenic mice","volume":"59","author":"Masuelli","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_591","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1186\/1479-5876-12-122","article-title":"Intratumoral delivery of recombinant vaccinia virus encoding for ErbB2\/Neu inhibits the growth of salivary gland carcinoma cells","volume":"12","author":"Masuelli","year":"2014","journal-title":"J. Transl. Med."},{"key":"ref_592","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/CJI.0b013e31817deafd","article-title":"Vaccination of prostate cancer patients with modified vaccinia ankara delivering the tumor antigen 5T4 (TroVax): A phase 2 trial","volume":"31","author":"Amato","year":"2008","journal-title":"J. Immunother."},{"key":"ref_593","doi-asserted-by":"crossref","first-page":"5539","DOI":"10.1158\/1078-0432.CCR-10-2082","article-title":"Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-controlled phase III study","volume":"16","author":"Amato","year":"2010","journal-title":"Clin. Cancer Res."},{"key":"ref_594","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/fon.12.7","article-title":"Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer","volume":"8","author":"Amato","year":"2012","journal-title":"Future Oncol."},{"key":"ref_595","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/CJI.0b013e3181e032c6","article-title":"Heterologous prime\/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression","volume":"33","author":"Ishizaki","year":"2010","journal-title":"J. Immunother."},{"key":"ref_596","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.vaccine.2010.12.016","article-title":"Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression","volume":"29","author":"Krupa","year":"2011","journal-title":"Vaccine"},{"key":"ref_597","doi-asserted-by":"crossref","first-page":"e878657","DOI":"10.1155\/2012\/878657","article-title":"The immunogenicity of the tumor-associated antigen alpha-fetoprotein is enhanced by a fusion with a transmembrane domain","volume":"2012","author":"Tran","year":"2012","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_598","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00262-010-0923-0","article-title":"Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model","volume":"60","author":"Ishizaki","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_599","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1128\/CVI.00678-13","article-title":"Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein","volume":"21","author":"Germain","year":"2014","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_600","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1128\/JVI.78.2.768-778.2004","article-title":"Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: Potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma","volume":"78","author":"Taylor","year":"2004","journal-title":"J. Virol."},{"key":"ref_601","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1089\/hum.1996.7.15-1853","article-title":"Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF","volume":"7","author":"Qin","year":"1996","journal-title":"Hum. Gene Ther."},{"key":"ref_602","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ymthe.2005.06.481","article-title":"Recombinant vaccinia virus expressing interleukin-2 invokes anti-tumor cellular immunity in an orthotopic murine model of head and neck squamous cell carcinoma","volume":"13","author":"Dasgupta","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_603","first-page":"326","article-title":"Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules","volume":"54","author":"Nemeckova","year":"2007","journal-title":"Neoplasma"},{"key":"ref_604","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00002371-199711000-00004","article-title":"Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity","volume":"20","author":"McLaughlin","year":"1997","journal-title":"J. Immunother."},{"key":"ref_605","first-page":"59","article-title":"Construction of recombinant vaccinia virus expressing GM-CSF and its use as tumor vaccine","volume":"3","author":"Qin","year":"1996","journal-title":"Gene Ther."},{"key":"ref_606","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s10637-008-9187-3","article-title":"MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure","volume":"27","author":"Dreicer","year":"2009","journal-title":"Investig. New Drugs"},{"key":"ref_607","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00262-011-1077-4","article-title":"> Immunotherapy with MVA-BN(R)-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells","volume":"61","author":"Mandl","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_608","first-page":"8751","article-title":"Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes","volume":"61","author":"McCart","year":"2001","journal-title":"Cancer Res."},{"key":"ref_609","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.ygyno.2014.01.009","article-title":"Oncolytic vaccinia virotherapy for endometrial cancer","volume":"132","author":"Liu","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"ref_610","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00000658-199909000-00008","article-title":"Regional versus systemic delivery of recombinant vaccinia virus as suicide gene therapy for murine liver metastases","volume":"230","author":"Gnant","year":"1999","journal-title":"Ann. Surg."},{"key":"ref_611","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/gt.2008.82","article-title":"Targeted delivery of a suicide gene to human colorectal tumors by a conditionally replicating vaccinia virus","volume":"15","author":"Foloppe","year":"2008","journal-title":"Gene Ther."},{"key":"ref_612","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.cgt.7701098","article-title":"Modified vaccinia virus Ankara as a vector for suicide gene therapy","volume":"15","author":"Erbs","year":"2008","journal-title":"Cancer Gene Ther."},{"key":"ref_613","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s00262-009-0686-7","article-title":"The immunologic aspects of poxvirus oncolytic therapy","volume":"58","author":"Worschech","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_614","doi-asserted-by":"crossref","first-page":"84","DOI":"10.4161\/bioe.22462","article-title":"Characterization and evaluation of a new oncolytic vaccinia virus strain LIVP6.1.1 for canine cancer therapy","volume":"4","author":"Gentschev","year":"2013","journal-title":"Bioengineered"},{"key":"ref_615","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1096\/fj.13-237222","article-title":"Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer","volume":"28","author":"Gholami","year":"2014","journal-title":"FASEB J."},{"key":"ref_616","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/ijc.28747","article-title":"Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF","volume":"135","author":"Hou","year":"2014","journal-title":"Int. J. Cancer"},{"key":"ref_617","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/mt.2013.240","article-title":"T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy","volume":"22","author":"Yu","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_618","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ymthe.2006.05.008","article-title":"Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF","volume":"14","author":"Kim","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_619","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1038\/mt.2011.132","article-title":"A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma","volume":"19","author":"Hwang","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_620","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"ref_621","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1371\/journal.pmed.0040353","article-title":"Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus","volume":"4","author":"Kirn","year":"2007","journal-title":"PLOS Med."},{"key":"ref_622","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/mt.2010.312","article-title":"Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer","volume":"19","author":"Li","year":"2011","journal-title":"Mol. Ther."},{"key":"ref_623","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/S0264-410X(02)00032-4","article-title":"Insertion of interleukin-2 (IL-2) and interleukin-12 (IL-12) genes into vaccinia virus results in effective anti-tumor responses without toxicity","volume":"20","author":"Kaufman","year":"2002","journal-title":"Vaccine"},{"key":"ref_624","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/cgt.2011.77","article-title":"Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer","volume":"19","author":"Sathaiah","year":"2012","journal-title":"Cancer Gene Ther."},{"key":"ref_625","doi-asserted-by":"crossref","first-page":"E1291","DOI":"10.1073\/pnas.1220580110","article-title":"Targeting CXCL12\/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases","volume":"110","author":"Gil","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_626","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/gt.2013.73","article-title":"CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging","volume":"21","author":"Parviainen","year":"2014","journal-title":"Gene Ther."},{"key":"ref_627","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1186\/1479-5876-8-40","article-title":"Fowlpox virus recombinants expressing HPV-16 E6 and E7 oncogenes for the therapy of cervical carcinoma elicit humoral and cell-mediated responses in rabbits","volume":"8","author":"Radaelli","year":"2010","journal-title":"J. Transl. Med."},{"key":"ref_628","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/978-1-4939-0345-0_32","article-title":"Making an avipoxvirus encoding a tumor-associated antigen and a costimulatory molecule","volume":"1139","author":"Howley","year":"2014","journal-title":"Methods Mol. Biol."},{"key":"ref_629","first-page":"1019","article-title":"Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine","volume":"8","author":"Menon","year":"2002","journal-title":"Clin. Cancer Res."},{"key":"ref_630","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/CJI.0b013e3181eccc87","article-title":"Preclinical qualification of a new multi-antigen candidate vaccine for metastatic melanoma","volume":"33","author":"Vogel","year":"2010","journal-title":"J. Immunother."},{"key":"ref_631","first-page":"2219","article-title":"Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas","volume":"6","author":"Arlen","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"ref_632","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/s002620000146","article-title":"Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule","volume":"49","author":"Horig","year":"2000","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_633","first-page":"1181","article-title":"The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma","volume":"7","author":"Arlen","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_634","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.4049\/jimmunol.165.12.7308","article-title":"Adoptive T cell immunotherapy of human uveal melanoma targeting gp100","volume":"165","author":"Sutmuller","year":"2000","journal-title":"J. Immunol."},{"key":"ref_635","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/cncr.21669","article-title":"Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100","volume":"106","author":"Spaner","year":"2006","journal-title":"Cancer"},{"key":"ref_636","doi-asserted-by":"crossref","first-page":"e109801","DOI":"10.1371\/journal.pone.0109801","article-title":"Myxoma Virus Expressing a Fusion Protein of Interleukin-15 (IL15) and IL15 Receptor Alpha Has Enhanced Antitumor Activity","volume":"9","author":"Tosic","year":"2014","journal-title":"PLOS ONE"},{"key":"ref_637","doi-asserted-by":"crossref","first-page":"e84134","DOI":"10.1371\/journal.pone.0084134","article-title":"Myxoma virus oncolytic efficiency can be enhanced through chemical or genetic disruption of the actin cytoskeleton","volume":"8","author":"Irwin","year":"2013","journal-title":"PLOS ONE"},{"key":"ref_638","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1016\/j.vaccine.2013.05.056","article-title":"Oncolytic myxoma virus: The path to clinic","volume":"31","author":"Chan","year":"2013","journal-title":"Vaccine"},{"key":"ref_639","doi-asserted-by":"crossref","first-page":"14453","DOI":"10.1073\/pnas.0606512103","article-title":"Recombinant vaccinia\/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients","volume":"103","author":"Jager","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_640","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1158\/1078-0432.CCR-05-2061","article-title":"Evaluation of prime\/boost regimens using recombinant poxvirus\/tyrosinase vaccines for the treatment of patients with metastatic melanoma","volume":"12","author":"Lindsey","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_641","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/sj.gt.3302124","article-title":"Local immunotherapy of spontaneous feline fibrosarcomas using recombinant poxviruses expressing interleukin 2 (IL2)","volume":"10","author":"Jourdier","year":"2003","journal-title":"Gene Ther."},{"key":"ref_642","first-page":"206","article-title":"Granulocyte\/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant","volume":"61","author":"Kass","year":"2001","journal-title":"Cancer Res."},{"key":"ref_643","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2217\/imt.13.176","article-title":"PROSTVAC(R) targeted immunotherapy candidate for prostate cancer","volume":"6","author":"Shore","year":"2014","journal-title":"Immunotherapy"},{"key":"ref_644","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1158\/2326-6066.CIR-13-0108","article-title":"Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer","volume":"2","author":"Gulley","year":"2014","journal-title":"Cancer immunol. Res."},{"key":"ref_645","doi-asserted-by":"crossref","first-page":"e28611","DOI":"10.4161\/onci.28611","article-title":"Poxviral-based vaccine elicits immunologic responses in prostate cancer patients","volume":"3","author":"Madan","year":"2014","journal-title":"Oncoimmunology"},{"key":"ref_646","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1200\/JCO.2000.18.23.3964","article-title":"Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses","volume":"18","author":"Marshall","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_647","first-page":"5800","article-title":"A triad of costimulatory molecules synergize to amplify T-cell activation","volume":"59","author":"Hodge","year":"1999","journal-title":"Cancer Res."},{"key":"ref_648","first-page":"5770","article-title":"Vector-based vaccine\/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity","volume":"62","author":"Aarts","year":"2002","journal-title":"Cancer Res."},{"key":"ref_649","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1517\/14712598.7.4.543","article-title":"PANVAC-VF: Poxviral-based vaccine therapy targeting CEA and MUC1 in carcinoma","volume":"7","author":"Madan","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_650","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/mt.2011.301","article-title":"ORFV: A novel oncolytic and immune stimulating parapoxvirus therapeutic","volume":"20","author":"Rintoul","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_651","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/mt.2010.14","article-title":"Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity","volume":"18","author":"Evgin","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_652","doi-asserted-by":"crossref","first-page":"10300","DOI":"10.1128\/JVI.75.21.10300-10308.2001","article-title":"Yaba-like disease virus: An alternative replicating poxvirus vector for cancer gene therapy","volume":"75","author":"Hu","year":"2001","journal-title":"J. Virol."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/4\/1726\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T20:44:22Z","timestamp":1760215462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/7\/4\/1726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,7]]},"references-count":652,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2015,4]]}},"alternative-id":["v7041726"],"URL":"https:\/\/doi.org\/10.3390\/v7041726","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,7]]}}}